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ABSTRACT 
Currently, there is no vaccine for Shigellosis. The Shiga-like toxoid 2, by itself, is poorly 
immunogenic. Flagellin based fusion proteins, serving as toll like receptor agonists, have shown 
both activation of innate immunity and an increase in adaptive immune responses from normally 
poorly immunogenic microenvironments. A synthetic flagellin based construct was designed to 
allow the insertion of detoxified antigen sequences, allowing multivalent expression and antigen 
presentation. Specifically, subunit B of shiga-like toxin 2, an Escherichia coli O157 
verocytotoxin, was chosen for co-expression alongside the construct for antigen specific 
presentation. The fusion protein, FliC-Stx2B, contains the innate activating synthetic FliC 
construct along with the genetically modified Stx2B toxoid.  
FliC-Stx2B amplicon DNA was produced through PCR while removing the associated 
signal peptide motif to prevent translocation and increase expression. Additionally, a hexa-
histidine affinity tag was incorporated downstream of the amplicon to further aid in purification. 
Positive clones were induced with varying amounts of IPTG to determine solubility of expressed 
protein. A detergent wash method, using heavy detergents, was then used to resolubilize & 
isolate FliC-Stx2B from cell culture pellets. Purification was conducted using ÄKTA® FPLC 
systems utilizing nickel column affinity. FliC-Stx2B was then refolded while on-column to 
revert the fusion protein to an intrinsic state, then eluted. Biological activity was determined 
using Western Blot, ELISA, & TLR5 assays.  
Over-expressed FliC-Stx2B was primarily found in insoluble fractions during culture 
induction studies. Non-desired proteins were removed from the induced insoluble cell pellet 
fractions during resolubilization, while also isolating FliC-Stx2B. The significant reduction in 
non-desired protein simplifies FliC-Stx2B purification further due to the addition of the hexa-
histidine tag, allowing for nickel column affinity. Purification yields for FliC-Stx2B is reported 
between 45-70% across varying on-column incubation time points. Binding of anti-Stx2B mAbs, 
seen in both Western blot and indirect-ELISA assay, confirms that FliC-Stx2B biological activity 
is maintained following both insoluble protein resolubilization & purification. Preliminary TLR5 
activity is seen in purified refolded FliC-Stx2B. These findings indicate that FliC-Stx2B retains 
its biological activity post-purification and could be a potential vaccine candidate. 
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1 INTRODUCTION  
1.1 Impact of Shigella spp. & Shigellosis  
There are currently no approved vaccines against Shigella spp., either cellular or subunit 
based. The Program for Appropriate Technology in Health (PATH, 2015) in their global report 
indicated that Shigella spp. & enterotoxigenic Escherichia coli based diseases may account for 
up to one billion cases of diarrheal episodes in both children and adults annually. The Centers for 
Disease Control (CDC, 2011) also estimates a minimum of 265,000 infections occur in the 
United States annually. Current detection methods are still being developed by the Global 
Enterics Multicenter Study (GEMS) foundation, amongst others, and infection rates may in fact 
be greater in number (Kotloff, et al., 2013). Investigators have recently shown that qualitative 
PCR (qPCR) methods indicated that the previously reported rate of 9.6% for Shigella spp. 
infections is actually considerably higher (Lindsay, et al., 2013). 
Shigella spp. based infections have been reported through GEMS to be one of four pathogens 
associated with moderate-to-severe diarrhea amongst children in sub-Saharan Africa and 
Southeast Asia; affecting all age groups but especially troublesome for children ages 5 and 
below, (Mani, et al., 2016; Ho, et al., 2013; Mead, 1999). The Child Health Epidemiology 
Reference Group (CHERG) and the Institute for Health Metrics and Evaluation (IHME) have 
reported that in endemic areas STEC caused as many as 28,000 deaths in 2011 & 34,400 deaths 
in 2013 in children ages 5, respectfully, (Lanata, et al., 2013). In age groups above 5 years, meta-
analysis suggests that an additional 40,000 deaths in these areas may also have been due to 
Shigella spp. infections. In older demographics, (Mani, et al., 2016; Lamberti, et al., 2014; 
Lanata, et al., 2013), STEC infections were in fact at a higher rate than both cholera and typhoid 
combined. In addition to people living in affected areas, travelers and military personnel are at 
2 
high risk when visiting these countries which also adds to the overall disease burden, (Mani, et 
al., 2016; Cohen, et al., 1988). Transmission is accomplished through person-to-person 
interactions or through the ingestion of contaminated food or water; there is no animal reservoir, 
(Mani, et al., 2016). 
In addition to mortality rates, IHME (2010) also reported that the overall disability-adjusted 
life years (DALYs) estimates associated with shigellosis has risen to 7 million, while years lived 
with disability (YLDs) has been estimated to be around 744,000. These estimates, aided by 
recent advancements in screening analysis, represent 7.8% of all diarrheal DALYs & 9% of all 
diarrheal YLDs for disease burden. 
 
1.2 Conjugate Shiga toxin-producing Escherichia coli (STEC) effects 
Shigella spp. present other forms of issues as well, having the ability for horizontal gene 
transfer between species or sister-species, (Brussow, et al., 2004). Specifically, between 
Escherichia coli and its sister-species Shigella dysenteriae; a dysenteric Gram-negative rod 
which uses its’ F-like pili to laterally transfer gene sequences between plasmids (Filloux, 2010; 
Miyake, 1962; Miyake & Demerec, 1959). This allows swapping of key genetic material 
amongst the related bacterium, further increasing its competitive evasiveness and complicating 
targeted vaccine development. When these bacteria conjugate, a Shiga-toxin producing strain of 
E. coli (STEC) is produced and may lead to shigellosis-like infections. It is also alternatively 
referred to as verocytotoxin-producing E. coli (VTEC). 
The recent increase in detectable instances of shigellosis & shigellosis-like infections, 
from Shigella spp. & STEC, warrants further attention in ways to combat diarrheal infections. 
Especially, in areas where clean water, food, and cold chain storage options are not available due 
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to harsh environments or by economic means. Transmission of STEC spp. is accomplished 
through person-to-person interactions or through the ingestion of contaminated food or water 
(Mani, S. et al., 2016). 
The effects of shiga toxin are similar in nature to that of Ricinus communis (Ricin toxin), 
causing malfunctions and alterations to ribosomes altering the production of protein (Sandvig, 
2000). Young patients or those with compromised immune systems may also develop hemolytic 
uremic syndrome (HUS) leading to acute kidney failure due to the death of renal cells 
(Houdouin, et al., 2004).  
HUS is characterized histologically through glomerular microvascular platelet adhesion 
aggregation/aggregation and the formation of fibrin polymers (Huang, et al., 2010). In addition, 
diarrhea associated HUS (D+HUS) also may include; thrombocytopenia, microangiopathic 
hemolytic anemia, acute renal failure. In the United States, acute renal failure affects children 
under the ages of 5 years old with a mortality rate of 3-5%, and is most commonly caused by 
D+HUS, (Huang et al., 2010; Tarr, et al., 2005; Garg, et al., 2003). 
 
1.3 Shiga toxin structure & mode of action  
The family of Shiga-like toxins expressed by STEC strains contain two groups designated 
Stx1 & Stx2. While only two groups exist, there are many sub-groups and serotypes. Stx2 has 
been shown epidemiologically to exhibit a higher rate of potency (100x) comparatively to Stx1 
(Scheutz, et al., 2012; Fuller, et al., 2011). Furthermore, patients infected with STEC strains 
expressing shiga toxin type 2 generally have a higher rate of developing D+HUS than those with 
Stx1based infections. Due to this, Stx2 has become a target for directed vaccination therapy, 
focusing on pre-attachment disruption. 
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X-ray crystallography has revealed that the Shiga toxin structural configuration normally 
presents as an AB5 complex (Fig. 1). A combination of the toxigenic A subunit (StxA) binds 
non-covalently to a B subunit (StxB) pentamer complex. The B subunit portion of the complex is 
associated with binding to cell surface receptors, specifically Globotriaosylceramide (Gb3), 
(Johannes & Römer, 2009; Fraser, et al., 1994; Stein, et al., 1992). StxA/Stx2B holotoxin 
construction is accomplished by insertion of StxA’s carboxyl terminus into the donut-shaped 
pentamer structure created by Stx2B formation during non-colavent assembly in the cell’s 
periplasm, (Johannes & Römer, 2009). 
Attachment of the holotoxin complex is vital for successful insertion into the host cell 
(Fig. 2). Shiga toxin AB5 complex uses the B subunit to attach to Gb3 receptors (CD77) located 
on the cell surface, and will attach to these receptors even in the absence StxA, (Johannes & 
Römer, 2009). Following attachment, the holotoxin is taken up via endocytosis into the cell for 
subsequent retrograde transport to the endoplasmic reticulum (ER), (Johannes & Römer, 2009; 
Sandvig, 2000). Retrograde translocation of the holotoxin allows for the A subunit to be released 
into the cytoplasm. From there Stx2A may cleave an adenine base located on the α-sarcin loop in 
eukaryotic ribosomes, then use the altered ribosome as substrate. This cleavage event prevents 
tRNA binding preventing translation of protein, (Johannes & Römer, 2009).  
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Figure 1.1 Shiga toxin AB5 structures (Johannes & Römer, 2009) 
 
 
 
Figure 1.2 Shiga toxin mechanism of action (Johannes & Römer, 2009) 
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1.4 STEC foodborne-illness outbreak risks 
A foodborne related outbreak is defined as an instance when two or more people get the 
same illness from the same contaminated food source, (CDC). More recently, foodborne related 
outbreaks have become more rampant due to the conjugative abilities of Shigella spp. and E. coli 
strains to produce the toxigenic strains of STEC. These strains, as mentioned previously, may 
illicit harmful symptoms such as; diarrhea, hemolytic uremic syndrome, fever, abdominal 
cramping, vomiting, and hemorrhagic colitis when infected, (Yang, et al., 2017; Kaper, et al., 
2004). Because of STEC’s ability to cause hemorrhagic colitis it is also commonly referred to as 
enterohemorrhagic E. coli (EHEC).  
The primary mechanism for transmission of STEC strains is through the direct ingestion 
of contaminated foods, or contact with infected ruminant animals, (Yang, et al., 2017). 
Transmission of STEC strains, however, differ than Shigella spp. due to the fact that Shigella 
spp. do not have an animal reservoir. This fact makes STEC a further reaching threat in 
comparison to Shigella spp. producing the shiga toxin. This is especially concerning in farms 
dedicated to mass food crop production where detection methods may not be fully 
encompassing. It also is possible to transmit STEC through person-to-person interactions, 
however close proximity is required.  
STEC infections are primarily foodborne and thrive over a wide range of temperatures, 
(Chaucheyras-Durand, et al. 2010). Infections are prevalent in cases where undercooked ground 
beef, raw milk, salads, raw leeks, vegetables, and fruits are the common food sources (Yang, et 
al., 2017; Herman, et al., 2015; Feng, 2014). Moreover, the amount of STEC cells necessary to 
become infectious is relatively low (CDC, 2010). With STEC’s ability to thrive in varying 
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temperatures, grow on common foods, and low ID50, the threat of STEC foodborne related 
outbreaks becomes increasingly problematic.  
Due to the conjugative relationship between Shigella spp. & E. coli many forms of STEC 
can be produced as a result of variable chance. The most commonly associated serotypes include, 
O26, O111, and O157 (Pennington, 2010). STEC O157:H7, however, is the serotype mostly 
associated with foodborne-illness outbreaks in the world, (Yang, et al., 2017). It has evolved 
over time to include both the Stx1 and Stx2 genes and virulence factors such as; intimin, 
translocated intimin receptors, type III secretion system, and hemolysis, (Yang, et al., 2017; 
Saitoh, et al., 2008). Recent STEC O157:H7 outbreaks affecting certain food crops grown for 
mass food supply have infected numerous individuals and has been fatal for some. Specifically, 
serotypes O104:H4, O157 PT8, O111:NM, and S. flexneri serotype 2 have caused instances of 
fatal infections in those infected, (Yang, et al., 2017). 
 
1.5 Current efforts against Shigellosis 
As stated previously, there are currently no approved vaccines against Shigella, either 
cellular or subunit based. One of the factors adding to the growing need for vaccine development 
lies with effective sanitation & hygiene for diarrheal prevention. However, in areas where clean 
water and medication is not accessible other means for disease prevention is further warranted. 
Cost benefit analyses have shown that vaccination therapy in comparison to cost-prohibitive 
water and sanitation infrastructure development may be a more viable option, especially in low-
income countries, (Mani, et al., 2016). Shigella spp. contain 50 different serotypes which all pose 
certain challenges when constructing a vaccine designed to be all-compassing, (Mani, et al., 
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2016; Livio, et al., 2014). A vaccine designed to have multivalent effects for high levels of 
protection is one way to increase overall coverage.  
Currently, there are several types of vaccine candidates against Shigella spp. being 
developed; cellular, glycoconjugate, novel antigen, & subunit based (Mani, et al., 2016). Cellular 
candidates have reached phase II clinical trials using a mutated virG-based live attenuated strain, 
(Venkatesan & Ranallo, 2016). Glycoconjugate candidates using O polysaccharides covalently 
linked to carrier glycoconjugates have reached phase III trials, (Pozsgay, et al., 1999). Novel 
candidates generally have focused on immune system priming through addition of Shigella spp. 
LPS or outer membrane vesicles with some form of transportation mechanism, (Mani, et al., 
2016). Candidates that use a subunit approach to illicit immune response represent the least 
amount of total vaccine candidates with only two reaching phase I clinical trials. PATH 
laboratories are currently testing a DB fusion protein that combines two T3SS antigens along 
with an invasion plasmid antigen, (Martinez-Becerra, et al., 2012). Another subunit based 
approach is seen in the NICED produced 34kDa OmpA vaccine candidate, which utilizes 
conserved and cross reactive Omps from Shigella flexneri 2a, (Pore & Chakrabarti, 2013).  
Subunit based candidates may also produce humoral protection, as they aim for antigen 
recognition during adaptive immune response, however have only been tested in animals. 
Specifically, PATH has been conducting trials on co-administration effects using a double-
mutant toxin (dmLT) adjuvant in order to initiate innate immune system responses when paired 
with the DB fusion protein (Mani, et al., 2016; Martinez-Becerra, et al., 2012). 
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1.6 Native Flagellin (FliC) background  
A need for enhanced vaccine candidates has risen due to the increase in antigenic evasion 
within patients presenting with poorly immunogenic defense mechanisms. Flagellin based 
vaccines serving as toll like receptor (TLR) agonists have shown increased efficacy over the 
years in increasing danger signals against non-self antigens within poorly immunogenic 
microenvironments, (Leigh, et al., 2012). Flagellin/TLR5 receptor interactions initiate an innate 
immune response which may then activate and mature antigen presenting cells (APCs) creating 
pro-inflammatory responses (Leigh, et al. 2014; Osterhaus, 2014; Sabag & Lorberboum-Galski, 
2014; Song, et al. 2014, Tarahomojoo, 2014). Specifically, modified multivalent flagellin 
platforms, FliC, that co-express detoxified antigenic sequences.  
FliC is a monomer protein of the flagellar protofilament used to form the molecular 
motor that allows locomotion in bacteria. The subunit is comprised of four domain regions (D0, 
D1, D2, and D3) that form a hairpin turn, creating a linear structure that reads N - Terminus, D0, 
D1, D2, D3, D2, D1, D0, C – Terminus (Fig. 3). It has been shown in previous research that Domains 
1 & 2 contain high affinity with TLR5 receptors and are highly conserved in many Gram-
negative bacteria such as Salmonella spp. (Song, et al., 2014; Mizel & Bates, 2010; Yoon, et al., 
2012; Donnelly & Steiner, 2002). The D3 region is not conserved or necessary for TLR5, and is 
therefore called the hypervariable region, (Liu, et al., 2010). 
By having high affinity for TLR5 receptors, FliC may initiate an innate immune response 
through activation and maturation of dendritic and natural killer cells, creating a pro-
inflammatory cytokine response within the microenvironment. FliC has shown potential as a 
vaccine adjuvant within models where poor immunogenicity persists, (Leigh, et al., 2014; 
Osterhaus, 2014; Sabag & Lorberboum-Galski, 2014: Song, et al., 2014; Tarahomjoo, 2013). 
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Specifically, modified fusion FliC platforms that may co-express non-toxic or detoxified 
antigenic sequences. 
 
 
 
Figure 1.3 Native FliC structure, cross-section, and top view (Lu & Swartz, 2016) 
 
1.7 Synthetic FliC platform  
To utilize the innate cell activating FliC platform, modifications were made to the N & C 
terminal D0 domains and the hypervariable D3 domain so that specific sequences may be inserted 
for co-expression, (Boyd, 2014; Gupta, et al., 2014; Osterhaus, 2014; Sabag & Lorberboum-
Galski, 2014; Song, et al., 2014). It has been shown in previous research that the FliC D1 domain, 
and portions of the D2 domain, were necessary for TLR5 activation whereas the D0 domain of 
both the N & C termini were not (Yoon, et al., 2012; Andersen-Neissen, et al., 2005; Smith, et 
al., 2003; Donnelly & Steiner, 2002). The D0 domain, therefore, was chosen to contain several 
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common restriction enzyme recognition sites for sequence insertions at either the N or C terminal 
ends of the modified FliC construct, (Boyd, 2014). 
Other research reported that replacing the hypervariable region with a DNA sequence of 
equal size allowed for the same levels of inflammation as native FliC. However, when DNA 
larger than the original hyper variable sequence was inserted, inflammation responses decreased. 
The D3 hypervariable domain aids in the spatial relationship of both D1 and D2 domains when 
interacting with TLR5 receptors. Therefore, changes in the hyper variable region for innate 
responses may be inhibited by size, (Liu, et al., 2010; Donnelly & Steiner, 2002; Eaves-Pyles, et 
al., 2001). Because of this, synthetic FliC contains a hypervariable D3 region the same length as 
the wild type. Moreover, in synthetic FliC restriction enzyme cut sites totaling six base pairs long 
are placed every 15 nucleotides, allowing compensation for gene insertion sizes (Boyd, 2014). In 
order to determine construct stability following hypervariable domain gene insertion a 
monomeric fluorescent protein (mRFP) construct was designed and inserted into synthetic FliC. 
 
 
 
Figure 1.4 Synthetic FliC cloning map (Boyd, 2014) 
12 
1.8 Stx2B-1N rationale and design  
As stated previously, flagellin based recombinant fusion protein vaccines serving as toll 
like receptor (TLR) agonists have shown increased efficacy in regard to generating an immune 
response. Because of this, the synthetic FliC platform was used in conjunction with the B-subunit 
of Shiga like toxoid 2 (Stx2B) to form Stx2B-1N, a bivalent recombinant based vaccine adjuvant 
candidate (Leigh, et al., 2014).   
Stx2B was modified, in silico, so that it could be to be inserted into the N’ terminal end 
of synthetic FliC, directly flanking the TLR5 activating D1 domain. In addition, to facilitate a 
more rapid purification of the desired recombinant protein a hexa-histidine tag was included into 
Stx2B-1N at the C’ terminal (D0 domain) end, which has been previously shown not to alter the 
epitope binding site affinity (D1 & D2 domains) associated with immune system priming, 
(Yoon, et al., 2012; Andersen-Neissen, et al., 2005; Donnelly & Steiner, 2002). 
 
1.9 FliC-Stx2B rationale and design  
Empirically, it has been shown that Stx2B secretory mechanisms involved in its 
translocation can excrete the protein either extracellularly or in cell-associated fractions in phage 
induced Enterohemorrhagic Escherichia coli (EHEC) models, similarly to Stx1 secretion, 
(Shimizu, et al., 2009). However, it also has been shown in previous studies that the addition of 
the type 3 secretion system (T3SS) signal peptide motif in both Stx A & B subunits may lead to 
excessive translocation of the protein into either membranous fractions or its’ conditioned media 
(Leung, et al., 2002; Skinner & Jackson, 1998). Purification attempts using constructs containing 
the associated signal peptide (Stx2B-1N) produced low purified product yields. In order to help 
prevent translocation issues, post-translation, the associated signal peptide sequence 
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(MKKMFMAVLFALASVNAMA) from the toxoid STx2B gene sequence was removed through 
polymerase chain reaction. With the removal of the signal peptide, sequestration of the desired 
protein remains cytoplasmic. Over-expressed FliC-Stx2B is found in insoluble form, collecting 
in inclusion bodies which have lower endotoxin units when compared to soluble protein 
fractions. Furthermore, significant overexpression of FliC-Stx2B is also seen in comparison to 
constructs retaining the signal peptide sequence (Stx2B-1N). 
In order to produce an industry level standard fusion protein to be used as a potential 
vaccine candidate, refolding of FliC-Stx2B is required due to it being insoluble. Refolding of 
FliC-Stx2B was designed to occur while on-column or during dialysis procedures. Refolding of 
the protein allows FliC-Stx2B to revert back to its’ intrinsic nature, prior to purification. On-
column refolding of the fusion protein also provides a more rapid purification process. 
 
1.10 FliC-Stx2B protein process methodology  
 
1.10.1 Enhanced cell clarification and protein isolation  
Over expressed FliC-Stx2B is primarily found, at high yield, in insoluble inclusion body 
fractions following cell culture induction. In order to isolate the fusion protein from insoluble 
fractions a detergent based method is used to facilitate separation. This isolation significantly 
removes non-desired protein from the final resolubilized sample, improving sample yields for 
further downstream processing & purifications 
 
1.10.2 Enhanced cell clarification and protein isolation  
Resolubilized FliC-Stx2B on-column refolding is combined with AKTA® FPLC 
purification to enhance and streamline previous insoluble protein purification methodologies. 
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Once adhered to the column, resolubilized FliC-Stx2B sample is gradually introduced to a 
refolding buffer, using a stepwise gradient, then allowed to incubate over time. This refolding 
process gently refolds the fusion protein allowing for greater hexa-histidine tag presentation to 
further aid in column binding. Previous refolding procedures required liters of refolding buffer 
and hours of subjugation.   
 
1.10.3 Biological activity profile characterization  
Characterization of a novel fusion protein is vital for viability assessment prior to further 
pre-clinical or animal model studies. Verification analysis was accomplished qualitatively 
through SDS-PAGE & Western blot (anti-stx2b). To characterize FliC-Stx2B biological activity 
indirect-ELISA, tested over a certain concentration gradient, was used to identify high-and-low 
concentration thresholds. 
 
 
Figure 1.5 Process overview 
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1.11 Objectives 
 
1.11.1 To design and develop a recombinant protein containing subunit B of shiga-like toxin 
2 located in a synthetic FliC platform for overexpression  
Genetic isolation of subunit B of shiga-like toxin 2 (Stx2B) from its origin AB5 complex 
removes toxicity associated with the toxigenic A subunit. Concurrent genetic removal of 
Stx2B’s TTSS signal peptide may produce an insoluble protein with toxoid classification.  
1.11.2 To reach an approach to optimize and enhance current methods used for extraction 
and resolubilization of the insoluble recombinant protein FliC-Stx2B 
By characterizing key factors involved with the insoluble extraction of FliC-Stx2B, an 
increase in yield may be obtained. These factors include: varying concentrations of urea 
used during detergent step washes, the amount of detergent washes utilized prior to 
resolubilization of the insoluble protein, and the intensity of shaking subjugated on the 
sample during the resolubilization phase.  
1.11.3 To determine and further characterize the innate & adaptive biological activity profile 
of FliC-Stx2B utilizing epitope affinity  
By design, FliC-Stx2B utilizes the Toll like receptor 5 activating synthetic FliC platform 
and the potentially humoral activating shiga-like toxin 2 subunit B. Through receptor 
affinity, TLR5 activation in HEK (human embryonic kidney) cells may be similar or 
equivalent to that of currently available protein standards used for academic and 
preclinical studies. Furthermore, utilizing resolubilization and refolding techniques, 
retention of biological activity against the Stx2B epitope domain may be similar to 
untreated samples. 
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2 METHODS & MATERIALS 
 
2.1 In silico design 
2.1.1 mRFP 
In order to insert mRFP into the synthetic FliC construct, in silico work was conducted to 
make sure there were no frame shifts or added stop codon sequences, post insertion. This was 
done by isolating the mRFP gene sequence from the psB1AC3 host plasmid provided by the 
iGEM laboratory at Georgia State University, shown below highlighted. 
 
Figure 2.1 pSB1AC3 host plasmid containing mRFP construct BBa-J04450 (iGEM, 2009) 
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Figure 2.2 Possible cloning sites for mRFP at N' & C', and hyper variable regions on R2 
construct 
 
 
 
 
ATGGCTTCCTCCGAAGACGTTATCAAAGAGTTCATGCGTTTCAAAGTTCGTATGGAAGGTTCCGTTA
ACGGTCACGAGTTCGAAATCGAAGGTGAAGGTGAAGGTCGTCCGTACGAAGGTACCCAGACCGCTA
AACTGAAAGTTACCAAAGGTGGTCCGCTGCCGTTCGCTTGGGACATCCTGTCCCCGCAGTTCCAGTA
CGGTTCCAAAGCTTACGTTAAACACCCGGCTGACATCCCGGACTACCTGAAACTGTCCTTCCCGGAA
GGTTTCAAATGGGAACGTGTTATGAACTTCGAAGACGGTGGTGTTGTTACCGTTACCCAGGACTCCT
CCCTGCAAGACGGTGAGTTCATCTACAAAGTTAAACTGCGTGGTACCAACTTCCCGTCCGACGGTCC
GGTTATGCAGAAAAAAACCATGGGTTGGGAAGCTTCCACCGAACGTATGTACCCGGAAGACGGTGC
TCTGAAAGGTGAAATCAAAATGCGTCTGAAACTGAAAGACGGTGGTCACTACGACGCTGAAGTTAA
AACCACCTACATGGCTAAAAAACCGGTTCAGCTGCCGGGTGCTTACAAAACCGACATCAAACTGGA
CATCACCTCCCACAACGAAGACTACACCATCGTTGAACAGTACGAACGTGCTGAAGGTCGTCACTC 
CACCGGTGCT 
Figure 2.3 mRFP in host plasmid pSB1AC3 nucleotide sequence (675 bp) 
 
 
Met A S S E D V I K E F Met R F K V R Met E G S V N G H E F E I E G E G E G R P Y E G T Q T A K L K 
V T K G G P L P F A W D I L S P Q F Q Y G S K A Y V K H P A D I P D Y L K L S F P E G F K W E R 
V Met N F E D G G V V T V T Q D S S L Q D G E F I Y K V K L R G T N F P S D G P V Met Q K K 
T Met G W E A S T E R Met Y P E D G A L K G E I K Met R L K L K D G G H Y D A E V K T T Y Met A K 
K P V Q L P G A Y K T D I K L D I T S H N E D Y T I V E Q Y E R A E G R H S T G A 
 
Figure 2.4 mRFP amino acid sequence (225 amino acids) 
  
 
 
18 
To enhance mRFP DNA amplification for insertion into the host plasmid, primers were 
designed to contain specific N’ terminal, C’ terminal, and hypervariable region restriction 
enzyme cut sites. This would allow no further modifications to the isolated gene following PCR 
prior to restriction enzyme digest.  
 
Forward primer 5’-3’ 
 
Buffer          NcoI                   BamHI        AatII            mRFP Sequence 
CAAGCACCATGGCCGGATCCGACGTCATGGCTTCCTCCGAAGACGTTATC 
 
Reverse primer 5’-3’  
Buffer         EcoRI            HindIII        AvrII         mRFP Sequence 
ATTCGTCTTAAGCTTCGAAGGATCCAGCACCGGTGGAGTGACGACCTTC 
 
Restriction Enzyme Legend 
 
NcoI EcoRI XbaI SpeI BamHI HindIII XhoI NotI AatII AvrII HisTag 
 
Figure 2.5 mRFP Primer Design 
 
 
 The isolated mRFP sequence was primarily designed to be inserted in between the 
restriction enzyme cut sites NcoI and EcoRI, located on the N' terminal domain of the synthetic 
FliC construct.  The proposed gene sequence was ran through ExPasy® translation software in 
order to determine if stop codons were produced with the theorized insertion design. 
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AGGAGGTAAAACACCATGGCCGGATCCGACGTCATGGCTTCCTCCGAAGACGTTATCAAAGAGTTC
ATGCGTTTCAAAGTTCGTATGGAAGGTTCCGTTAACGGTCACGAGTTCGAAATCGAAGGTGAAGGT
GAAGGTCGTCCGTACGAAGGTACCCAGACCGCTAAACTGAAAGTTACCAAAGGTGGTCCGCTGCCG
TTCGCTTGGGACATCCTGTCCCCGCAGTTCCAGTACGGTTCCAAAGCTTACGTTAAACACCCGGCTG
ACATCCCGGACTACCTGAAACTGTCCTTCCCGGAAGGTTTCAAATGGGAACGTGTTATGAACTTCGA
AGACGGTGGTGTTGTTACCGTTACCCAGGACTCCTCCCTGCAAGACGGTGAGTTCATCTACAAAGTT
AAACTGCGTGGTACCAACTTCCCGTCCGACGGTCCGGTTATGCAGAAAAAAACCATGGGTTGGGAA
GCTTCCACCGAACGTATGTACCCGGAAGACGGTGCTCTGAAAGGTGAAATCAAAATGCGTCTGAAA
CTGAAAGACGGTGGTCACTACGACGCTGAAGTTAAAACCACCTACATGGCTAAAAAACCGGTTCAG
CTGCCGGGTGCTTACAAAACCGACATCAAACTGGACATCACCTCCCACAACGAAGACTACACCATC
GTTGAACAGTACGAACGTGCTGAAGGTCGTCACTCCACCGGTGCTCCTAGGAAGCTTCGAATTCGGT
CTAGAACTAGTGCAGCCGGCCAGGCGATTGCGAATCGTTTTACGGCGAACATCAAGGGTCTGACCC
AAGCCTCTCGTAATGCAAATGATGGTATTAGCATCGCACAAACCACCGAAGGCGCGCTGAACGAGA
TCAACAATAACTTGCAACGTGTCCGTGAGCTGGCAGTTCAGAGCGCGAACAGCACGAATAGCCAGT
CCGATTTGGACAGCATCCAGGCGGAGATTACGCAACGTTTGAACGAAATCGACCGCGTCAGCGGTC
AAACGCAGTTTAATGGTGTGAAAGTTCTGGCCCAGGATAACACCCTGACGATTCAGGTTGGCGCAA
ACGACGGTGAAACGATTGATATTGACCTGAAGCAGATCAACAGCCAAACCCTGGGTCTGGACACCC
TGAACGTGCAACAAAAGTATAAGGTGTCGGACACGGCCGCTACCGTGACCGGCGACGTCGATACTA
CGATTGCTGGGCCCAATAGTACTTTTAAAGCTAGCGCTACTGGTCTTGGTGAGCTCGACCAGAAAAT
TGATCATATGTTAAAATTTGATGATCAATTGGGAAAATATTACGCCCCGCGGACCGTTACGGGGGG
ACGATCGAAAGATGGCTATTATACCGGTTCCGTTGATAAGACGGCATGCGAGGTGACTCTTGCTGTG
CACGCGACTTCCCCGCTTACGCGTGGACTACCTGCGACAAGATCTGAGGATGTGAAAAATCCTAGG
GTTGCCAACGCTGACCTGACCGAGGCGAAAGCGGCGCTGACCGCAGCGGGCGTTACTGGTACCGCA
AGCGTTGTGAAAATGAGCTACACCGACAATAATGGTAAAACTATCGATGGCGGTCTGGCGGTCAAA
GTCGGCGACGACTACTATTCCGCCACCCAGAACAAAGACGGCAGCATCAGCATTAACACTACGAAA
TACACCGCAGATGACGGCACGAGCAAAACGGCACTGAATAAGCTGGGCGGTGCGGATGGTAAGAC
CGAAGTTGTTAGCATTGGTGGTAAAACCTATGCCGCGTCCAAGGCAGAGGGTCACAATTTCAAGGC
GCAGCCGGATCTGGCGGAAGCTGCAGCGACCACGACCGAGAATCCGTTGCAGAAGATTGATGCGGC
GCTGGCACAGGTCGATACGCTGCGCTCTGACCTGGGTGCCGTACAAAACCGTTTCAATAGCGCGAT
CACCAATCTGGGCAACACCGTGAACAATCTGACCTCTGCTCGCAGCCGTATTGAGGGATCCAAGCTT
CTCGAGTAGGCGGCCGCAAGC 
Figure 2.6 Synthetic FliC construct with mRFP in N’ terminus (2,007 bp) 
 
 
 
R R Stop N T Met A G S D V Met A S S E D V I K E F Met R F K V R Met E G S V N G H E F E I E G E G E 
G R P Y E G T Q T A K L K V T K G G P L P F A W D I L S P Q F Q Y G S K A Y V K H P A D I P D Y L K 
L S F P E G F K W E R V Met N F E D G G V V T V T Q D S S L Q D G E F I Y K V K L R G T N F P S D G 
P V Met Q K K T Met G W E A S T E R Met Y P E D G A L K G E I K Met R L K L K D G G H Y D A E V K 
T T Y Met A K K P V Q L P G A Y K T D I K L D I T S H N E D Y T I V E Q Y E R A E G R H S T G A P R K 
L R I R S R T S A A G Q A I A N R F T A N I K G L T Q A S R N A N D G I S I A Q T T E G A L N E I N N N 
L Q R V R E L A V Q S A N S T N S Q S D L D S I Q A E I T Q R L N E I D R V S G Q T Q F N G V K V L A 
Q D N T L T I Q V G A N D G E T I D I D L K Q I N S Q T L G L D T L N V Q Q K Y K V S D T A A T V T G 
D V D T T I A G P N S T F K A S A T G L G E L D Q K I D H Met L K F D D Q L G K Y Y A P R T V T G G 
R S K D G Y Y T G S V D K T A C E V T L A V H A T S P L T R G L P A T R S E D V K N P R V A N A D L 
T E A K A A L T A A G V T G T A S V V K Met S Y T D N N G K T I D G G L A V K V G D D Y Y S A T Q 
N K D G S I S I N T T K Y T A D D G T S K T A L N K L G G A D G K T E V V S I G G K T Y A A S K A E 
G H N F K A Q P D L A E A A A T T T E N P L Q K I D A A L A Q V D T L R S D L G A V Q N R F N S A I 
T N L G N T V N N L T S A R S R I E G S K L L E Stop A A A S 
Figure 2.7 Synthetic FliC with mRFP amino acid sequence (661 amino acids) 
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2.1.2 Stx2B-1N stepwise PCR 
Initially, primers were designed utilizing a step wise method, incorporating flanking DNA 
restriction enzyme cut sites during each round of PCR to produce insert DNA that may be 
incorporated into N’ & C’ terminal domains (Appendix A.1). The initial round of PCR added 
BamHI (C’ terminal) and SpeI (N’ terminal) restriction enzyme cut sites, while the second round 
added NcoI (N’ terminal) and NotI (C’ terminal). The third round of PCR added 12 buffer base 
pairs on both upstream and downstream ends of the Stx2B gene of interest. 
  
2.1.3 Stx2B-1N single round PCR 
In order to enhance Stx2B amplification from the pJ204 host plasmid, seen above with 
step wise PCR, primers specific of the gene of interest were redesigned for increased specificity. 
The following computational programs were used to assess and verify the in silico work for 
primer design; ExPASy© bioinformatic translation tool (for verification of frame shift errors), 
IDT optimized codon tool (highest optimization of nucleotide sequence for E. coli), and 
NEBcutter® (restriction enzyme cut site finder).    
 
 
STx2B nucleotide sequence (267 bp) 
ATGAAGAAGATGTTTATGGCGGTTTTATTTGCATTAGCTTCTGTTAATGCAATGGCGGCGGATTGTG
CTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGACACATTTACAGTGAAGGTTGACGGGA
AAGAATACTGGACCAGTCGCTGGAATCTGCAACCGTTACTGCAAAGTGCTCAGTTGACAGGAATGA
CTGTCACAATCAAATCCAGTACCTGTGAATCAGGCTCCGGATTTGCTGAAGTGCAGTTTAATAATGA 
C 
 
STx2B Translated sequence (89 Amino acids)  
Met K K Met F Met A V L F A L A S V N A Met A A D C A K G K I E F S K Y N E D D T F T V K V D G K 
E Y W T S R W N L Q P L L Q S A Q L T G Met T V T I K S S T C E S G S G F A E V Q F N N D 
 
Figure 2.8 Stx2B nucleotide & amino acid sequences 
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Forward (STX2BFWDN) 
CGCGCACCATGGTTATGAAGAAGATGTTTATGGCG 
 
Reverse (STX2BREVN) 
CGCCGCCGCACTAGTGTCATTATTAAACTGCACTTC 
 
NcoI- CCATGG 
SpeI- ACTAGT 
 
Figure 2.9 Optimized Stx2B-1N primer design 
 
AGGAGGTAAAACACCATGGTTATGAAGAAGATGTTTATGGCGGTTTTATTTGCATTAGCTTCTGTTA
ATGCAATGGCGGCGGATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGACACAT
TTACAGTGAAGGTTGACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCAACCGTTACTGCAAA
GTGCTCAGTTGACAGGAATGACTGTCACAATCAAATCCAGTACCTGTGAATCAGGCTCCGGATTTGC
TGAAGTGCAGTTTAATAATGACACTAGTGCAGCCGGCCAGGCGATTGCGAATCGTTTTACGGCGAA
CATCAAGGGTCTGACCCAAGCCTCTCGTAATGCAAATGATGGTATTAGCATCGCACAAACCACCGA
AGGCGCGCTGAACGAGATCAACAATAACTTGCAACGTGTCCGTGAGCTGGCAGTTCAGAGCGCGAA
CAGCACGAATAGCCAGTCCGATTTGGACAGCATCCAGGCGGAGATTACGCAACGTTTGAACGAAAT
CGACCGCGTCAGCGGTCAAACGCAGTTTAATGGTGTGAAAGTTCTGGCCCAGGATAACACCCTGAC
GATTCAGGTTGGCGCAAACGACGGTGAAACGATTGATATTGACCTGAAGCAGATCAACAGCCAAAC
CCTGGGTCTGGACACCCTGAACGTGCAACAAAAGTATAAGGTGTCGGACACGGCCGCTACCGTGAC
CGGCGACGTCGATACTACGATTGCTGGGCCCAATAGTACTTTTAAAGCTAGCGCTACTGGTCTTGGT
GAGCTCGACCAGAAAATTGATCATATGTTAAAATTTGATGATCAATTGGGAAAATATTACGCCCCG
CGGACCGTTACGGGGGGACGATCGAAAGATGGCTATTATACCGGTTCCGTTGATAAGACGGCATGC
GAGGTGACTCTTGCTGTGCACGCGACTTCCCCGCTTACGCGTGGACTACCTGCGACAAGATCTGAGG
ATGTGAAAAATCCTAGGGTTGCCAACGCTGACCTGACCGAGGCGAAAGCGGCGCTGACCGCAGCGG
GCGTTACTGGTACCGCAAGCGTTGTGAAAATGAGCTACACCGACAATAATGGTAAAACTATCGATG
GCGGTCTGGCGGTCAAAGTCGGCGACGACTACTATTCCGCCACCCAGAACAAAGACGGCAGCATCA
GCATTAACACTACGAAATACACCGCAGATGACGGCACGAGCAAAACGGCACTGAATAAGCTGGGC
GGTGCGGATGGTAAGACCGAAGTTGTTAGCATTGGTGGTAAAACCTATGCCGCGTCCAAGGCAGAG
GGTCACAATTTCAAGGCGCAGCCGGATCTGGCGGAAGCTGCAGCGACCACGACCGAGAATCCGTTG
CAGAAGATTGATGCGGCGCTGGCACAGGTCGATACGCTGCGCTCTGACCTGGGTGCCGTACAAAAC
CGTTTCAATAGCGCGATCACCAATCTGGGCAACACCGTGAACAATCTGACCTCTGCTCGCAGCCGTA
TTGAGGGATCCCACCACCATCATCACCATCTCGAGTAGGCGGCCGCAAGC 
Figure 2.10 Stx2B-1N nucleotide sequence containing hexa-histidine tag (1,572 bp) 
 
R R Stop N T Met V Met K K Met F Met A V L F A L A S V N A Met A A D C A K G K I E F S K Y N E D D 
T F T V K V D G K E Y W T S R W N L Q P L L Q S A Q L T G Met T V T I K S S T C E S G S G F A E V Q 
F N N D T S A A G Q A I A N R F T A N I K G L T Q A S R N A N D G I S I A Q T T E G A L N E I N N N L 
Q R V R E L A V Q S A N S T N S Q S D L D S I Q A E I T Q R L N E I D R V S G Q T Q F N G V K V L A Q 
D N T L T I Q V G A N D G E T I D I D L K Q I N S Q T L G L D T L N V Q Q K Y K V S D T A A T V T G D 
V D T T I A G P N S T F K A S A T G L G E L D Q K I D H Met L K F D D Q L G K Y Y A P R T V T G G R 
S K D G Y Y T G S V D K T A C E V T L A V H A T S P L T R G L P A T R S E D V K N P R V A N A D L T 
E A K A A L T A A G V T G T A S V V K Met S Y T D N N G K T I D G G L A V K V G D D Y Y S A T Q N 
K D G S I S I N T T K Y T A D D G T S K T A L N K L G G A D G K T E V V S I G G K T Y A A S K A E G 
H N F K A Q P D L A E A A A T T T E N P L Q K I D A A L A Q V D T L R S D L G A V Q N R F N S A I T 
N L G N T V N N L T S A R S R I E G S H H H H H H L E Stop A A A S 
Figure 2.11 Stx2B-1N containing hexa-histidine tag translated sequence (516 amino acids) 
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2.1.4 FliC-Stx2B 
The gene of interest, Shiga-like toxoid 2 (Stx2B), was isolated from a genetically 
encoded host plasmid pJ204 (ATUM®), via polymerase chain reaction). Forward and reverse 
primers (Stx2B-1CF & Stx2B-1CR) were designed and synthesized with BamHI & XhoI 
restriction enzyme cut sites, respectfully, to amplify the toxoid gene Stx2B. The reverse primer 
Stx2B-1CR also incorporated a hexa-histidine tag, immediately flanked by restriction enzyme 
cut sites, to aid in downstream isolation and purification. Amplified Stx2B was designed to be 
inserted into vector pJ404 (ATUM®) which incorporates a pUC based origin of replication, a 
phage T5 derived inducible promoter, and ampicillin resistance (Appendix A.1, A4).  
Previous Stx2B constructs utilizing the synthetic FliC platform, (Stx2B-1N), were 
analyzed in order to enhance the development & expression of the fusion protein (Appendix 
A.1). A signal peptide motif (MKKMFMAVLFALASVNAMA), associated with type three 
section systems (TTSS), was identified within the toxoid gene Stx2B and removed through 
deletion PCR to further enhance the expression and isolation of the fusion protein. Furthermore, 
Stx2b was inserted into the C-terminal end of the synthetic FliC platform to enhance Stx2B 
epitope presentation (Appendix A.1, A4). 
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Figure 2.12 FliC-Stx2B cloning map 
 
 
STx2B nucleotide sequence (267 bp) 
GCGGATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGACACATTTACAGTGAAG
GTTGACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCAACCGTTACTGCAAAGTGCTCAGTTG
ACAGGAATGACTGTCACAATCAAATCCAGTACCTGTGAATCAGGCTCCGGATTTGCTGAAGTGCAG
TTTAATAATGAC 
 
STx2B Translated sequence (70 Amino acids)  
A D C A K G K I E F S K Y N E D D T F T V K V D G K E Y W T S R W N L Q P L L Q S A Q L T G Met T V 
T I K S S T C E S G S G F A E V Q F N N D 
 
Figure 2.13 Stx2B nucleotide & amino acid sequences without signal peptide motif 
 
 
 
 
Forward STX2B 1CF (with signal peptide) 51bp 
 
GCGTACGGATCCGCGGATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTAT 
 
Reverse STX2B 1CR (without signal peptide) 60 bp 
 
TACGTGCTCGAGATGGTGATGATGGTGATGGTCATTATTAAACTGCACTTCAGCAAATCC 
 
Restriction Enzyme Map 
 
NcoI EcoRI XbaI SpeI BamHI HindIII XhoI NotI AatII AvrII HisTag  
 
Figure 2.14 FliC-Stx2B primer design HisTag 
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AGGAGGTAAAACACCATGGGAATTCGGTCTAGAACTAGTGCAGCCGGCCAGGCGATTGCGAATCGT
TTTACGGCGAACATCAAGGGTCTGACCCAAGCCTCTCGTAATGCAAATGATGGTATTAGCATCGCAC
AAACCACCGAAGGCGCGCTGAACGAGATCAACAATAACTTGCAACGTGTCCGTGAGCTGGCAGTTC
AGAGCGCGAACAGCACGAATAGCCAGTCCGATTTGGACAGCATCCAGGCGGAGATTACGCAACGTT
TGAACGAAATCGACCGCGTCAGCGGTCAAACGCAGTTTAATGGTGTGAAAGTTCTGGCCCAGGATA
ACACCCTGACGATTCAGGTTGGCGCAAACGACGGTGAAACGATTGATATTGACCTGAAGCAGATCA
ACAGCCAAACCCTGGGTCTGGACACCCTGAACGTGCAACAAAAGTATAAGGTGTCGGACACGGCCG
CTACCGTGACCGGCGACGTCGATACTACGATTGCTGGGCCCAATAGTACTTTTAAAGCTAGCGCTAC
TGGTCTTGGTGAGCTCGACCAGAAAATTGATCATATGTTAAAATTTGATGATCAATTGGGAAAATAT
TACGCCCCGCGGACCGTTACGGGGGGACGATCGAAAGATGGCTATTATACCGGTTCCGTTGATAAG
ACGGCATGCGAGGTGACTCTTGCTGTGCACGCGACTTCCCCGCTTACGCGTGGACTACCTGCGACAA
GATCTGAGGATGTGAAAAATCCTAGGGTTGCCAACGCTGACCTGACCGAGGCGAAAGCGGCGCTGA
CCGCAGCGGGCGTTACTGGTACCGCAAGCGTTGTGAAAATGAGCTACACCGACAATAATGGTAAAA
CTATCGATGGCGGTCTGGCGGTCAAAGTCGGCGACGACTACTATTCCGCCACCCAGAACAAAGACG
GCAGCATCAGCATTAACACTACGAAATACACCGCAGATGACGGCACGAGCAAAACGGCACTGAAT
AAGCTGGGCGGTGCGGATGGTAAGACCGAAGTTGTTAGCATTGGTGGTAAAACCTATGCCGCGTCC
AAGGCAGAGGGTCACAATTTCAAGGCGCAGCCGGATCTGGCGGAAGCTGCAGCGACCACGACCGA
GAATCCGTTGCAGAAGATTGATGCGGCGCTGGCACAGGTCGATACGCTGCGCTCTGACCTGGGTGC
CGTACAAAACCGTTTCAATAGCGCGATCACCAATCTGGGCAACACCGTGAACAATCTGACCTCTGCT
CGCAGCCGTATTGAGGGATCCGCGGATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAG
GATGACACATTTACAGTGAAGGTTGACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCAACCG
TTACTGCAAAGTGCTCAGTTGACAGGAATGACTGTCACAATCAAATCCAGTACCTGTGAATCAGGCT
CCGGATTTGCTGAAGTGCAGTTTAATAATGACCATCACCATCATCACCATCTCGAGTAGGCGGCCGC
AAGC 
Figure 2.15 FliC-Stx2B without signal peptide nucleotide sequence (1527 bp) 
 
 
R R Stop N T Met G I R S R T S A A G Q A I A N R F T A N I K G L T Q A S R N A N D G I S I A Q T T E G 
A L N E I N N N L Q R V R E L A V Q S A N S T N S Q S D L D S I Q A E I T Q R L N E I D R V S G Q T Q 
F N G V K V L A Q D N T L T I Q V G A N D G E T I D I D L K Q I N S Q T L G L D T L N V Q Q K Y K V 
S D T A A T V T G D V D T T I A G P N S T F K A S A T G L G E L D Q K I D H Met L K F D D Q L G K Y 
Y A P R T V T G G R S K D G Y Y T G S V D K T A C E V T L A V H A T S P L T R G L P A T R S E D V K 
N P R V A N A D L T E A K A A L T A A G V T G T A S V V K Met S Y T D N N G K T I D G G L A V K V 
G D D Y Y S A T Q N K D G S I S I N T T K Y T A D D G T S K T A L N K L G G A D G K T E V V S I G G 
K T Y A A S K A E G H N F K A Q P D L A E A A A T T T E N P L Q K I D A A L A Q V D T L R S D L G A 
V Q N R F N S A I T N L G N T V N N L T S A R S R I E G S A D C A K G K I E F S K Y N E D D T F T V K 
V D G K E Y W T S R W N L Q P L L Q S A Q L T G Met T V T I K S S T C E S G S G F A E V Q F N N D H 
H H H H H L E Stop A A A S 
Figure 2.16 Translated FliC-Stx2B without signal peptide motif amino acid sequence (501 
amino acids) 
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2.2 Cloning  
 
Amplification of each gene of interest was conducted using Thermo Scientific® master mix 
kit & thermocycler conditions. Volumes used for each reaction are shown in Appendix A.2. The 
amplified samples were then loaded and ran on a 1% agarose DNA gel at 80V for 90 minutes in 
1X TAE buffer, using Tridye® 1kb ladder for analytical comparison.  
Restriction enzyme digests were conducted by incubating the isolated amplicon DNA 
samples with New England BioLabs® (NEB) restriction enzymes for 2.5 hours at 37°C, then 
placed on ice. In order to prevent over-cutting, a reaction clean-up was conducted on digest 
samples using a Qiagen® reaction clean-up kit to remove excess restriction enzymes and buffers. 
Digest samples were then subsequently quantified and ligated using Thermo Scientific rapid DNA 
ligation kit® (K1422) at an insert to vector ratio of either 1:3, 1:5, or 1:8.  
Ligation samples were purified using a Qiagen® QIAquick gel extraction kit prior to 
transformation into New England BioLabs® E. coli (BL21) cells, which were made electro-
competent.  Two microliters of each insert to vector ratio sample was then mixed with 40µLs of 
electro-competent E. coli (BL21) cell suspension then electrically pulsed using a Bio-Rad 
MicroPulsar™. The samples were then allowed to recover in 1mL super optimal broth (SOB) 
medium at 37°C with gentle agitation (225 rpm). Recovered cells were then plated onto Luria 
Broth (LB) agar plates with 100µg/mL ampicillin to counter select against non-positive clones. 
Plates were grown at 37°C for 24-36 hours prior to analysis.  
Conformational analysis was conducted using quadrant/colony PCR, restriction enzyme 
digest against BamHI & XhoI restriction enzymes, & DNA sequencing.  
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2.3 Protein work 
 
2.3.1 Adaptation of Stx2B-1N & FliC-Stx2B expressing E. coli to adaptation media (ECAM) 
 
 
Confirmed clones were adapted to synthetic E. coli adaptation media (ECAM), see 
Appendix A.4, through several culture passages. A 100mL Luria broth (LB, Appendix A.4) 
overnight culture with 100ug/mL ampicillin was inoculated with either Stx2B-1N or FliC-Stx2B 
positive clone and allowed to grow at 37°C with gentle agitation (225 rpm) until an OD600 of 
~1.2-1.7 was reached. The overnight culture was then used as an inoculum for a 1st pass ECAM 
culture, to achieve an initial OD600 of 0.1. The 1
st pass culture was again allowed to reach an 
OD600 of ~1.2-1.7 and was then used to inoculate the 2
nd pass ECAM culture at a starting OD600 
of 0.1. Once the OD600 of the 2
nd pass reached 0.7, the culture was spun down and resuspended in 
sterile phosphate-buffered saline, then stored at -80°C. 
2.3.2 Protein expression and sample processing 
 
Cell culture for recombinant FliC-Stx2B protein expression was prepared by transferring 
confirmed transformant glycerol stocks onto fresh LB plates containing 100ug/mL ampicillin for 
bacterial counter-selectivity, then left in an incubator at 37°C overnight. A single colony from 
the LB plates was then used to inoculate an overnight culture of either Luria broth, Terrific broth 
(TB), or ECAM media (with 100µg/mL ampicillin), then left to incubate in an orbital shaker at 
225rpm & 37°C. Overnight culture optical densities were then obtained and used to calculate the 
volume of inoculum to inoculate the working culture, containing the same media type and 
antibiotics as the overnight culture, to a starting OD600 of 0.1. 
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The working culture was subjected to the same culturing parameters as the overnight 
culture. Once an OD600 of 0.6-0.7 was reached in the working culture, it was induced with either 
0.4mM or 1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) then left to incubate at 37°C and 
225rpm for either 3, 6, or 18 hours. One culture flask receiving no IPTG was also grown 
alongside induced cultures to determine uninduced protein expression.    
Samples were then centrifuged in a Beckman Coulter® Allegra 64R centrifuge for 10 
minutes at 10k rpm at 4°C to remove media and cell debris. Following centrifugation, the 
supernatant was carefully decanted to isolate the cell pellet which was then resuspended in 10mL 
sterile PBS buffer and stored at -80°C. Insoluble and soluble protein fractions were separated 
following the addition of 0.142mL Roche® cOmplete mini (EDTA-Free) protease cocktail 
mixture, to prevent protein degradation, by sonication (3x) and subsequent centrifugation. The 
soluble fraction was then decanted and stored for future analysis, while the insoluble cell pellet 
was resuspended in equal volume lysis buffer (50mM Tris, 8M urea) and 0.142mL protease 
cocktail mix. Insoluble fractions were then sonicated three times and stored for analysis at -80°C. 
 
2.3.3 Denaturing SDS-PAGE analysis 
 
Induced and uninduced sonicated suspensions were quantified using Thermo Scientific® 
Pierce BCA protein assay kit. Quantified samples were then heated for 10 minutes at 95°C and 
centrifuged in an Eppendorf® 5415 D centrifuge at 13k rpm for five minutes to remove insoluble 
protein debris. To further denature the samples, 10µL of NuPAGE® 4x denaturing LDS dye was 
added to 30µL of protein sample. Samples were then loaded on a NuPAGE® 4-12% Bis-Tris gel 
and ran for one hour at a constant 200 volts, with 1X MOPS as the running buffer. The gel was 
stained with 150mL of 0.1% Coomassie Brilliant Blue R-250 working solution then heated in a 
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microwave, on full power, for 1 minute and left shaking (50rpm) for 15 minutes. Following 
Coomassie staining, the gel was transferred into 150mL destain solution and microwaved for 1 
minute then placed on an orbital shaker at 50rpm.  
 
2.3.4 Cell disruption & clarification using detergent wash method for insoluble protein 
resolubilization  
 
Following induction of cells, the cell suspension was centrifuged to gather cell pellet then 
washed once with 10mL sterile PBS solution prior to freezing in liquid nitrogen. Frozen cell 
suspension was placed on ice and left at 4°C overnight to gently thaw and lyse the cells. After 
thawing overnight, cell suspension was centrifuged again (10k rpm at 4°C) for 10 minutes to 
collect the pellet, then resuspended with either 4mL or 40mL of resuspension buffer (20mM 
Tris-HCl, pH 8.0).  
Resuspended cell suspensions were then sonicated three times for 10 second intervals (1 
sec on/ 0.5 ½ off duty cycles), then subsequently centrifuged in a Beckman Coulter® Allegra 64R 
centrifuge for 10 minutes at 10k rpm and 4°C. The supernatant (containing the soluble protein 
fraction) was then decanted and stored for SDS-PAGE analysis.  
The insoluble protein faction was then resuspended with either 3mL or 30mL of 
detergent based isolation buffer (2M urea, 20mM Tris-HCl, 0.5M NaCl, 2% Triton X-100, pH 
8.0) at 4°C, then sonicated and centrifuged as done previously. The supernatant was then 
decanted and sampled for SDS-PAGE analysis. Detergent buffer wash step may then be repeated 
to further the isolation of FliC-Stx2B. Five milliliters, or 50mL, of Binding buffer solution 
(20mM Tris-HCl, 0.5M NaCl, 20mM Imidazole, 2M-6M guanidine hydrochloride, 1mM DTT, 
pH 8.0) was used to resolubilize the insoluble pellet, following detergent wash steps. Samples 
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were agitated on an orbital shaker (50-250rpm) at room temperature for 60 minutes, then 
centrifuged for 15 minutes at 10k rpm and 4°C. Prior to fast protein liquid chromatography 
(FPLC) purification, the resolubilized pellet sample was filtered through a 0.2uM filter and 
stored for later passage through a GE healthcare life sciences® HisTrap HP 1mL nickel column.  
 
2.3.5 Dialysis refolding 
 
Two milliliters of protein sample, resolubilized with 2M guanidine hydrochloride, was 
gently introduced into ~2 inches of Spectra/Por® molecularpourous membrane tubing which 
were clipped at the ends with Spectra/Por® closures. The dialysis tubing was then placed into 
beaker containing 400mL (200X of sample volume) refolding buffer (20mM Tris-HCl, 0.5M 
NaCl, 20mM Imidazole, 1mM DTT, 0-6M urea, pH 8.0) and a stir bar. The apparatus was stored 
at 4°C overnight and allowed to spin gently using the vortex produced through magnetic stirring. 
Guanidine hydrochloride removal was assessed through the addition of NuPAGE® LDS (lithium 
dodecyl sulfate) Sample Buffer. 
  
2.3.6 Induced cell pellet preparation for Hydrophobic Interaction Column (HIC) 
 
Induced cell pellet samples were resuspended in resuspension buffer then sonicated three 
times as described previously. Samples were then diluted using a 1:1 equal ratio of either lysis 
buffer B80 (50mM Tris, 125mM NaCl, 10mM EDTA, 4% sucrose) or Super Q equilibration 
buffer (100mM Tris 2.3M NaCl). Sample mix was then filtered through a 0.2-micron filter to 
prevent debris from entering AKTA® FPLC tubing. 
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2.3.7 Fermentation cell paste processing for AKTA® FPLC purification 
 
Stx2B expressing E. coli fermentation paste was processed into a refined partially 
purified lysate by using the following steps: 1) homogenization, 2) PEG precipitation, and 3) 
Triton X-114 2-phase separation under the following parameters.  
150 grams (wet wt.) of fermentation paste, harvested following a 5-hour induction using 
1mM IPTG, was resuspended in 1L of B80 lysis buffer (Appendix A.4) and allowed to stir on ice 
for 30 minutes until the mixture became less turbid. Prior to the addition of the cell mixture, lysis 
buffer (B80) was added to the APV homogenizer to equilibrate it, while maintaining the pressure 
at 0 Bar. The lysate was then passed through the homogenizer three times at 720 bar, with the 
exception of the first pass which remained at 0 bar to ease the homogenization process on the 
cells. Between each pass, the lysate temperature was maintained at 4°C by placing it into pre-
chilled 250mL bottles then submerging them into an ethanol ice bath.  
Following homogenization, the cell lysate was centrifuged in a Beckman Coulter® Avanti 
J-20 XPI centrifuge at 10k rpm for 1 hour at 4°C to separate cell debris from the desired protein. 
The supernatant was collected and used for polyethylene glycol (PEG 3350) precipitation, while 
the pellet was resuspended in PBS and used for analysis. Four percent (w/v) PEG 3350 was 
added to the supernatant in a dual-beaker apparatus slowly, containing ice to maintain 
temperature, and allowed to dissolve fully and then stirred for 30 minutes. Lysate was then spun 
down for at 10k rpm for 1 hour at 4°C to separate out proteins. The supernatant volume was 
measured, and stored for later analysis. The pellet produced was then resuspended with pellet 
resuspension buffer (B57, Appendix A.4) at ½ the supernatant volume and stirred until fully 
dissolved. The lysate was then centrifuged in a Beckman Coulter® Allegra 64R at 10k rpm for 1 
hour at 4°C. Supernatant and pellet fractions were separated for Triton X-114 treatment.  
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One percent (w/v) Triton X-114 was added to the supernatant which was then allowed to 
stir at room temperature for 30 minutes prior to being placed into a water bath set at 30°C for 10 
minutes. The pellet produced was resuspended in 10mL PBS and stored for future analysis. 
Following the water bath, the lysate was then centrifuged in a Beckman Coulter® Allegra 64R at 
10k rpm for 4 hours at room temperature with the brake to the centrifuge disabled, allowing for a 
slow regression in speed over time. After braking overnight, the aqueous phase top layer was 
extracted and filtered through a 0.2um PES filter, thus producing the refined lysate needed for 
AKTA® FPLC purification. The remaining pellet was again resuspended in 10mL PBS and 
stored for future analysis.  
 
2.3.8 FPLC purification 
 
Purification of recombinant FliC-Stx2B was conducted using a GE Healthcare and Life 
Sciences® HisTrap HP 1mL nickel column which has affinity for the hexa-histidine tag located 
on the C-terminal end of the construct.  
Prior to sample loading, 10mL of binding buffer was used to equilibrate the column to 
increase the HisTrap HP nickel column’s binding affinity. Three milliliters of filtered, 
resolubilized protein described above, was then loaded onto the column using a flow rate of 
0.3mL/min being careful not to saturate the column. Ten milliliters of Solubilization buffer 
(20mM Tris-HCl, 0.5M NaCl, 20mM Imidazole, 1mM DTT, 6M urea, pH 8.0, Appendix A.4) 
was then added through the column at 0.3mL/min to wash away any unbound or non-specific 
proteins from the column. 
Due to the nature of the protein being insoluble, a refolding step was included in order to 
purify protein with the highest intrinsic biological activity possible. A step-wise gradient of 
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refolding buffer (20mM Tris-HCl, 0.5M NaCl, 20mM Imidazole, 1mM DTT, 0-6M urea, pH 8.0, 
Appendix A.4) was applied starting from a concentration of 6M urea to 0M urea, using 
0.3mL/min as the flow rate. Once the gradient reached 0M urea, the column containing bound 
FliC-Stx2B was allowed to incubate on-column for either 1, 2, 3, or 6 hours prior to a 5mL 
refolding buffer wash and an imidazole step-wise gradient elution.  
Elution was conducted using 20mL of an elution buffer gradient (20mM Tris-HCl, 0.5M 
NaCl, 20-500mM Imidazole, 1mM DTT, pH 8.0, Appendix A.4) starting from 20mM imidazole 
and ending at 500mM imidazole with a flow rate of 0.3mL/min. Samples were collected in 20% 
increments of the step-wise gradient and stored in 2mL aliquots to be analyzed by SDS-PAGE.  
 
2.3.9 Western blot analysis 
 
Prior to nitrocellulose membrane transfer, a denaturing SDS-PAGE was conducted using 
the same parameters described in denaturing SDS-PAGE analysis. Upon completion of the gel, a 
filter paper sandwich was assembled consisting of Novex® Nitrocellulose membrane filter paper 
sandwich and the SDS-PAGE gel. 
Protein transfer from the SDS-PAGE gel to the nitrocellulose membrane was conducted 
using NuPAGE® transfer buffer & an Invitrogen® XCell II blot module set at a constant 30V for 
1 hour under cold temperature. The nitrocellulose membrane was removed following the protein 
transfer and placed into 100mL of (1X) TBST milk solution (20mM Tris-HCl, 0.15mM NaCl, 
1% Triton X-100, 5% nonfat dry milk) then left overnight on an orbital shaker (50rpm) at 4°C. 
Following overnight shaking, the membrane was washed using room temperature (1X) TBST for 
10 minutes (3x) at 70rpm.  
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Primary antibodies were diluted in (1X) TBST milk solution at a working ratio of 1: 
1,000. The antibody mixture was then applied while shaking at 50rpm for 1 hour at room 
temperature, then subsequently washed again with (1X) TBST milk solution at 70rpm. Diluted 
secondary antibody, prepared the same way as the primary solution, was applied for 1 hour at 
50rpm then washed again with 1X TBST three times. The membrane was then coated with 
PerkinElmer™ Western Lightning® ECL Pro chemiluminescence substrate, and incubated in the 
dark for 5 minutes. ImagineQuant® LAS 4000 mini software systems were used to visualize 
chemilluminescence reactions. 
 
2.3.10 Indirect ELISA analysis 
 
In order to characterize FliC-Stx2B epitope activity, an ELISA assay was conducted 
using a protein concentration range of 250ng-3.9ng. Following diluting samples in ELISA 
coating buffer (0.5M Carbaonate-Bicarbonate, pH 9.6, Appendix A.4), 50µL of each desired 
sample concentration was then plated on a Costar® 96 well plate, in triplicate, and incubated at 
4°C overnight. Samples were then aspirated by gently, but swiftly, inverting the plate to remove 
any liquids from the wells. Each well was then washed with 150µL PBST (0.05% Tween 20 in 
Phosphate-buffered saline) three times, to remove any unbound proteins. 60µL of blocking 
buffer (PBST with 5% nonfat dry milk, Appendix A.4) was then added to each well following 
aspiration and allowed to incubate at 37°C for 1 hour. 
 After incubation, the wells were aspirated and washed as described previously. Primary 
antibody, at a working concentration of 1:2000 in blocking buffer, was then added to each well 
and allowed to incubate at 37°C for 1.5 hours. The plate was then aspirated and washed again to 
prepare for the addition of the secondary antibody mix using the same parameters as the primary 
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antibody wash. A final wash step was conducted prior to the addition of 100µL/well 
eBioscience® (1X) TMB ELISA substrate solution, then allowed to incubate at room temperature 
for three minutes in the dark. The reaction was then stopped with the addition of 100uL/well 1M 
phosphoric acid and read on a Wallac® Victor2 1420 multilabel counter at an optical density of 
450nm.  
  
 
 
Figure 2.17 Process Overview 
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3 RESULTS 
 
3.1 Amplification of mRFP 
Following amplification of mRFP via polymerase chain reaction (PCR), subsequent DNA 
was then ran on a 1% DNA Agarose gel to determine whether in silico primer design was 
accurate. mRFP is 760bp in length with the addition of both forward and reverse primers. mRFP 
amplicon DNA bands were seen between 0.5 kilobases and 1.0 kilobases when compared to 
Tridye® DNA ladder. In Fig. 3.1, it is seen in the highlighted region that amplified mRFP 
migrates towards ~700bp. 
 
 
Figure 3.1 mRFP amplified DNA from host plasmid pJ204 
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3.2 Transformation of mRFP into electro-competent E. coli  
Following inoculation of the transformed cell mixture onto antibiotic-selective Luria 
broth plates containing ampicillin, colony growth began to occur after 24 hours of incubation at 
37°C. The colonies were off white in color and spherical in shape, much like the control 
competent E. coli colonies that were grown on LB plates without antibiotics. Control plates did 
not show growth of competent E. coli indicating transformants (Fig. 3.2) contained the antibiotic 
resistance encoding pJ404 plasmid. 
 
 
Figure 3.2 mRFP transformant colony growth 24 hours post transformation on LB ampicillin 
(100µg) plates 
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Putative transformant colonies were carefully isolated using a sterile toothpick then 
resuspended in 50µL diH2O prior to colony PCR. The samples were then ran on a 1% DNA 
Agarose gel in 1X TAE (Appendix A.4) for insert confirmation. It is seen in Fig. 3.3 that test 
samples in lanes 2-20, putative transformant colonies containing mRFP/pJ404, showed banding 
at ~ 0.7 kilobases when compared to Tridye® 1kb ladder. Primer dimer formation is also seen 
towards the bottom of the DNA agarose gel.  Lanes 22-26 showed no banding in control samples 
containing nuclease free water and forward and reverse primers. Lanes 27 and 28 contained 
amplified mRFP DNA from the previous PCR (Fig. 3.1) and presented with the same banding 
patterns at ~0.7 kilobases. 
 
 
 
Figure 3.3 Colony PCR on mRFP transformant colonies 
Lanes 1, 21, 29) Ladder. Lanes 2-20) Transformant colonies expressing mRFP. Lanes 22-26) Nuclease free 
water with primers. Lanes 27, 28: Previously amplified mRFP DNA. 
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3.3 Amplification & restriction digest verification of Stx2B-1N  
Previous attempts at amplifying the toxoid gene Stx2B from its host plasmid pJ204 
proved troublesome and produced insufficient DNA yields. Therefore, primers redesigned for 
optimal adherence & specificity were incubated with varying concentrations of template DNA to 
produce higher yields of amplified DNA (Fig. 3.4). As it is seen in Fig. 3.4 the varying 
concentrations of template DNA illustrated a gradient like effect on the amplification of Stx2B 
from pJ204. In Fig. 3.4 (lanes 2 and 3) amplification of Stx2B can be seen, however in lane 3 a 
non-specific band appears at ~1.5 kilobases. This same band is seen more prominently in lane 4, 
as template DNA concentration increases, while the ~300bp Stx2B band seen in previous lanes 
disappears.  
Restriction digest products for Stx2B and synthetic FliC (in host plasmid pJ404), seen in 
Fig. 3.5, showed expected band migration for both double cut pJ404 plasmid and amplified 
Stx2B DNA.  
 
 
 
Figure 3.4 Optimized Stx2B-1N PCR conducted using varying levels of template DNA 
Lanes 1-8) Tridye 1kb DNA ladder. Lane 2) 100ng template DNA. Lane 3) 300ng template DNA. Lane 4) 
500ng template DNA. 
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Figure 3.5 Restriction digest on Stx2B host plasmid pJ204 and synthetic FliC 
Lanes 1 & 7) Tri-dye DNA ladder. Lanes 2 & 3) Double digest pJ404/R2. Lanes 4-6) Double digest Stx2B. 
 
 
3.4 Transformation of Stx2B-1N into electro-competent E. coli - 
Using restriction Stx2B & pJ404 restriction digest products, ligation and transformation 
was conducted and grew transformant colonies on antibiotic-selective Luria broth plates 
containing ampicillin. No growth was seen on control plates containing transformed digested 
vector plasmid with no DNA ligase, and with samples transformed solely with the electro-
competent E. coli cells. Colonies were cream in color, indicative of previous E. coli colonies 
seen before (Fig. 3.2). Colony forming units for the plates inoculated with either 1:3 or 1:8 molar 
ratio ligations ranged in number, forming more colonies on the higher insert to vector ratio 
reactions. 
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Quadrant colony PCR, performed on various colonies per quadrant, yielded amplified 
Stx2B insert DNA from each sample set as seen (Fig. 3.6A & 3.6B).  Due to these results, 
isolated colony PCR was conducted (Fig. 3.7) in order to isolate and verify colonies for 
subsequent verification analysis. Similar to Fig. 3.5, all tested transformant colonies showed the 
amplification of the gene of interest.  
 
 
 
 
 
Figure 3.6 Quadrant colony PCR conducted on Stx2B-1N transformant colonies for both 1:3 
and 1:8 molar ratio ligations 
(A) Lanes 1 and 8) Tri-dye DNA ladder. Lanes 2-4) 1:3 ligation ratio with 100µL inoculum. Lanes 5-7) 
1:8 ligations with 50µL inoculum. (B) Lanes 1 and 7) Tri-dye DNA ladder. Lane 2) 1:8 ligation with 
50µL ligation inoculum. Lanes 3-6) 1:8 ligations with 100µL inoculum.  
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Figure 3.7 Isolated colony PCR conducted on Stx2B-1N transformant colonies  
Lanes 1 and 7) Tri-dye DNA ladder. Lanes 2-6) isolated colony PCR samples chosen from positive quadrant 
PCR.  
 
 
3.5 Initial Stx2B-1N nickel column purification  
Following Stx2B-1N protein expression (Appendix A.3, A12-A14), cell lysate samples 
were analyzed for the solubility of the recombinant protein before and after passage through a 
nickel column in both soluble and insoluble fractions (Fig. 3.8).  
Presence of Stx2B-1N is shown to be associated more with soluble cell fractions 
(supernatant & treated pellet lanes) in comparison to the insoluble pellet samples (untreated 
pellet & resuspension lanes). Stx2B-1N recombinant protein collects predominately in elution 
fraction lanes 3 & 4, however excess protein banding persists albeit reduced in comparison to 
flow through lanes. 
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Figure 3.8 Initial Stx2B-1N FPLC nickel column purification  
Lane 1) thawed cell pellet sample alone. Lane 2) resuspended cell pellet from lane 1. Lane 3) cell pellet 
supernatant following centrifugation prior to purification Lane 4) cell pellet prior to purification. Lane 5) 
AKTA© flow through. Lanes 6-8) flow through fractions 1 & 3. Lanes 9-13) Eluted fractions.  
 
Due to the excess of non-desired protein banding in the eluted fractions (Fig. 3.8) 
optimization of imidazole concentrations within the binding buffer was conducted (Fig. 3.9). 
Binding buffers containing varying concentrations of imidazole were used (5mM & 20mM 
respectfully) in order to inhibit competitive binding of non-desired proteins to the HisTrap 
column during AKTA® FPLC. Purification using binding buffer with an imidazole concentration 
at 5mM (Fig. 3.9A) showed elution of excess proteins and Stx2B-1N more prominently than the 
initial purification (Fig. 3.8). When using binding buffer with an imidazole concentration at 
20mM, however, excess non-desired protein banding decreased but still remained (Fig. 3.9B).  
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Figure 3.9 Stx2B-1N nickel column purification using varying concentrations of imidazole 
during binding 
(A) AKTA© purification using 5mM (left) & (B) 20mM imidazole (right) for binding activity respectfully.  
 
 
3.6 Stx2B-1N fermentation paste refined lysate fraction analysis  
Prior to protein purification, fermentation cell paste was produced, harvested, and 
processed into a refined lysate in order to prevent blocking of AKTA® FPLC capillary tubes. The 
refined lysate also acts to further isolate and remove excess non-desired protein and cell debris. 
As it is seen in the Western blot (Fig. 3.10B), the appearance of a protein with a molecular 
weight at ~38kDa is still the most abundantly present. Interestingly, a second protein band is also 
present at ~60kDa in the PEG 3350 and Triton X-114 treated samples as the excess non-desired 
protein bands decrease. This ~60kDa protein is also seen during cell sample processing prior to 
producing the refined lysate (Fig. 3.10). 
 
 
 
44 
 
Figure 3.10 Stx2B-1N refined lysate SDS-PAGE & Western blot analysis (anti-FliC ab)  
(A) Lane 1) Page Ruler Ladder. Lane 2) Cell lysate prior to homogenization. Lane 3) First pass through 
homogenizer. Lane 4-6) 2nd – 4th pass. Lane 7) Centrifuged supernatant. Lane 8) Resuspended pellet 
following centrifugation. Lane 9) PEG centrifuged supernatant. Lane 10) Resuspended PEG pellet 1. 
Lane 11) Resuspended PEG pellet 2. Lane 12) Aqueous phase. Lane 13) Detergent phase. Lane 15) 
Magic Mark Protein Standard. (B) Anti-FliC Western Blot using the same lane designations as figure (A).  
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3.7 Transformation & analysis of FliC-Stx2B into electro-competent E. coli  
Putative transformant colonies produced through restriction digest, ligation, and 
subsequent transformation via electroporation, were subjugated to colony PCR (Fig. 3.11). 
Individual transformant colony DNA, incubated with both forward and reverse primers specific 
for the toxoid gene Stx2B, showed amplification of Stx2B in all fractions tested (Fig. 3.11, lanes 
2-8).  
PCR confirmed transformant colonies were then subjected to restriction enzyme digest to 
verify the insertion of Stx2B, using both BamHI & XhoI restriction cut sites for both single & 
double restriction digest (Fig. 3.12). As it is seen in Fig. 3.12 (lanes 5 & 6) restriction double 
digest conducted on plasmid DNA isolated from transformant colonies produced the ~300bp 
Stx2B inserted gene. Isolated plasmid DNA cut with BamHI (Fig. 3.12, lane 7) showed one 
single band, similar to the control single digest (Fig. 3.12, lane 2).  
 
Figure 3.11 Isolated colony PCR conducted on FliC-Stx2B transformant colonies 
Lanes 1) Tri-dye DNA ladder. Lanes 2-8) Isolated FliC-Stx2B transformant colonies subjected to PCR.  
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Figure 3.12 Restriction enzyme digest verification on FliC-Stx2B & pJ404 
Lane 1) Tridye® 1kb ladder. Lane 2) pJ404 single digest. Lane 3 & 4) pJ404 double digest. Lane 5)  
FliC-Stx2B double digest. Lane 6) FliC-Stx2B double digest. Lane 7) FliC-Stx2B uncut plasmid.  
Lane 8) 100bp ladder.    
 
3.8 FliC-Stx2B Expression  
Following molecular cloning and verification procedures, induction studies were 
conducted on both Stx2B-1N & FliC-Stx2B constructs to determine if exclusion of the signal 
peptide motif, associated with the Stx2B toxoid, has an effect on protein expression (Fig. 3.13). 
Stx2B-1N contains the detoxified STx2B gene with its’ signal peptide motif inserted into the N – 
terminus of the synthetic FliC construct, whereas FliC-Stx2B contains no signal peptide motif 
and is cloned into the C – terminus. The induced insoluble fractions (Fig. 3.13, lanes 3 & 4) 
show expression of both Stx2B-1N & FliC-Stx2B recombinant proteins, in comparison to the 
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uninduced fractions. However, the level of expression seen in FliC-Stx2B is more significant in 
comparison to Stx2B-1N. Expression is also seen in the soluble protein fractions in lanes 6 & 7, 
however slight. 
 
 
 
Figure 3.13 Stx2B-1N & FliC-Stx2B E. coli 3-hour induction in E. coli adaptation media 
Stx2B-1N: Lane 1) Page-Ruler Protein Ladder. Lane 2-4) uninduced & induced (0.4mM, 1.0mM IPTG) 
insoluble protein fractions. Lane 5-7) uninduced & induced (0.4mM, 1.0mM IPTG) soluble protein 
fractions. All lanes loaded with 5ug of protein. FliC-Stx2B: Lane designations and protein fractions 
same as Stx2B-1N. Stx2B-1N & FliC-Stx2B molecular weight ~ 53kDa. 
 
 
Because of the significant expression seen with the FliC-Stx2B construct, an induction 
trial utilizing three media types (Luria Broth, Terrific Broth, & ECAM minimal media, Appendix 
A.4) was conducted (Fig. 3.14). The same parameters used in Fig. 3.13 were also used for this 
study. The level of expression shown with FliC-Stx2B is present within the insoluble fractions 
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(Fig. 3.14, lanes 3 & 4) in each of the three mediums tested, however expression levels were 
lower in Luria-Broth cultures. Reduction in non-FliC-Stx2B proteins in expressed lanes 3 & 4 is 
also shown in comparison to the uninduced insoluble fractions (Fig. 3.14, lane 1) and the 
uninduced & induced soluble fractions (Fig. 3.14, lanes 5-7). Each 100mL culture yielded ~1.0g 
(wet wt.) of cell pellet. 
 
 
 
Figure 3.14 FliC-Stx2B E. coli 3-hour induction samples in LB, TB, & ECAM media 
FliC-Stx2B LB. Lanes 1 & 8) Page-Ruler Protein Ladder. Lanes 2-4) uninduced & induced (0.4mM, 
1.0mM IPTG) insoluble protein fractions. Lane 5-7) Uninduced & induced (0.4mM, 1.0mM IPTG) 
soluble protein fractions. FliC-Stx2B TB & ECAM: Lane designations and protein fractions consistent 
with FliC-Stx2B LB. 
 
 
3.9 Insoluble FliC-Stx2B clarification & resolubilization - 
Due to the insolubility of FliC-Stx2B, a modified detergent wash method was utilized 
containing both urea (pellet wash steps) and guanidine hydrochloride (resolubilization step) 
detergents, in order to isolate FliC-Stx2B from insoluble inclusion bodies immediately following 
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cell disruption (Fig. 3.15). For both TB media & ECAM culture samples, an incremental 
reduction in non-desired protein is observed against the soluble protein fractions (Fig. 3.15, lanes 
2-4, 7-10). Resolubilized pellet lanes also show greater reduction of non-desired proteins 
following pellet detergent wash steps. Resolubilized sample bands (Fig. 3.15, lanes 5 & 10) also 
appear curved due to the addition of guanidine hydrochloride.  
To determine the applicability of the modified detergent wash method, tested culture 
volumes were increased to 100mL & 1L, respectfully, in comparison to small-scale 10mL 
cultures (Fig. 3.16).  Similar to Fig. 3.15, the up-scaled modified detergent wash method shown 
in Fig. 3.16 shows a significant reduction in non-desired protein banding, along with significant 
isolation of FliC-Stx2B from the insoluble inclusion body pellet. The corresponding Western 
blot also indicates the presence of biologically active FliC-Stx2B (Fig. 3.16B, lanes 3-6 & 9-12). 
This is seen not only at the predicted molecular weight, but in higher molecular weight polymer 
bands.  
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Figure 3.15 FliC-Stx2B Cell Clarification & Detergent Wash in Terrific Broth and ECAM 
Lanes 1, 6, & 11) Page-Ruler protein ladder. Lanes 2 & 7) Soluble protein fraction. Lanes 3,4 & 8,9) 
Pellet detergent wash fractions. Lanes 5 & 10) Resolubilized FliC-Stx2B insoluble protein.  
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Figure 3.16 SDS-PAGE & Western Blot on FliC-Stx2B Cell Clarification using 100mL & 1L 
Culture Pellets in Terrific Broth 
(A) Lanes 1, 7, & 13) Page-Ruler protein ladder. Lanes 2 & 8) Soluble protein fraction. Lanes 3,4 & 
9,10) Pellet detergent wash fractions. Lanes 5 & 11) Resolubilized FliC-Stx2B insoluble protein (10ug). 
Lanes 6 & 12) Resolubilized FliC-Stx2B insoluble protein (5ug). (B) All lanes correspond to (A). Anti-
Stx2B primary mAb was used at a ratio of 1: 1,000. 
 
 
 
3.10 FliC-Stx2B on-column purification with biological activity analysis  
In order to refold resolubilized FliC-Stx2B back to its intrinsic form, an on-column 
purification procedure was utilized using AKTA® FPLC systems. The step-wise refolding & 
elution gradient washes (Fig. 3.17, lanes 4, 5, 7, & 14) show no removal of the bound His-tagged 
FliC-Stx2B from the nickel column. Moreover, refolded FliC-Stx2B was eluted at both 60% & 
80% increments during the step-wise elution gradient (Fig. 3.17, lanes 10 & 11).  
Following AKTA© FPLC purification and refolding, purified FliC-Stx2B was then de-
salted using Amicon filters with a molecular weight cut off of 30kDa. An Enzyme Linked 
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Imunno Absorbent assay was then conducted on both pre-AKTA© (resolubilized) and purified 
FliC-Stx2B samples to determine whether or not the on-column refolding step proved efficacious 
in maintaining anti-Stx2B biological activity. As it is shown in Fig. 3.18, purified FliC-Stx2B 
shows a higher rate of activity in almost all samples tested. The activity profile seen with pre-
AKTA© samples also contain ~50% less total activity in comparison to refolded samples.  
 
 
 
 
Figure 3.17 FliC-Stx2B FPLC Purification 
Lanes 1 & 15) Page-Ruler protein ladder. Lane 2) Resolubilized FliC-Stx2B insoluble protein. Lane 9) 
Purified FliC-Stx2B at 60% imidazole elution. Lane 10) Purified FliC-Stx2B at 80% imidazole elution. 
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Figure 3.18 FliC-Stx2B resolubilized & purified Indirect-ELISA 
Purified FliC-Stx2B samples tested over a concentration range of 3ng to 500ng. 
 
 
 
3.11 FliC-Stx2B on-column refolding time study & biological activity analysis 
To determine the optimal incubation period for FliC-Stx2B on-column refolding, a time 
study was conducted using three separate 1mL HisTrap Nickel columns in alternating lines using 
AKTA® FPLC systems concurrently (Fig. 3.19A). Purified & refolded FliC-Stx2B was eluted 
again in a step-wise gradient at both 60% & 80% increments, further characterizing elution 
conditions (Fig. 3.17). Higher molecular weight FliC-Stx2B polymer proteins, identified in Fig. 
3.16B, was also positively identified in the corresponding Western blot, indicating the presence 
of biologically active FliC-Stx2B throughout each refolding time-point.   
A Western blot & indirect ELISA, specifically targeting the Stx2B epitope domain, was 
conducted using purified FliC-Stx2B samples from the 1 and 6-hour on-column refolding 
incubation (Fig. 3.19A & 3.19B) with a concentration range of 250ng-3.9ng for in vitro analysis 
(Fig. 3.20). There was little difference seen between 1-hour and 6-hour on-column incubation 
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samples, however at each tested concentration set the 1-hour incubated FliC-Stx2B samples 
contained higher biological activity in comparison to 6 hours of incubation.  
Preliminary in vitro analysis comparing FliC-Stx2B’s ability to activate innate immunity 
associated TLR5 receptors, expressed in HEK293 cells, against control FljB protein is seen in 
Fig. 3.21. Tested samples were added to confluent HEK293 cells, then observed at an optical 
density of 630nm after a time period of ten minutes.  
 
 
 
 
 
Figure 3.19 SDS-PAGE & Western Blot for FliC-Stx2B FPLC purified protein 
(A) Lanes 1 & 9) Page-Ruler protein ladder. Lane 2) 1-hour incubated FliC-Stx2B purified protein 
loaded with 5ug. Lane 4) 1-hour incubated FliC-Stx2B purified protein loaded with 10ug. Lane 6) 6-hour 
incubated FliC-Stx2B purified protein loaded with 10ug. (B) All lanes correspond to (A). Anti-Stx2B 
primary mAb was used at a ratio of 1: 1,000.  
 
 
 
55 
 
 
 
 
 
Figure 3.20 FliC-Stx2B refolding study ELISA 
1 & 6-hour purified FliC-Stx2B protein tested over a concentration range of 250ng-3.9ng 
 
 
 
Figure 3.21 FliC-Stx2B TLR5 in vitro assay 
1-hour purified FliC-Stx2B fusion protein, & control FljB, TLR5 activity against TLR5 receptor 
expressing human embryonic kidney cells (HEK293). Tested samples observed at OD630 after 
10 minutes. 
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3.12 FliC-Stx2B dialysis refolding  
Treated cell culture pellet samples were induced, clarified, and processed in order to 
isolate the insoluble fusion protein FliC-Stx2B (Fig. 3.22). Following separation of both soluble 
and insoluble fractions, FliC-Stx2B remains primarily in the insoluble pellet rinse fraction (Fig. 
3.22, lanes 2 & 3). This retention is shown throughout both pellet rinse washes and the 
resolubilized protein fraction (Fig. 3.22, lanes 3-5). Removal of non-desired proteins is also seen 
in the final resolubilized protein fraction (Fig. 3.22A & 3.22B).  
 
 
Figure 3.22 FliC-Stx2B expression, cell clarification, & isolation using varying 
concentrations of detergent 
(A) 2M Guanidine hydrochloride. Lane 1) Page-Ruler Protein Ladder. Lane 2) Soluble protein fraction. 
Lane 3 & 4) Insoluble protein fraction from pellet rinse washes using 2M Urea. Lane 5) Resolubilized 
insoluble protein fraction using 2M Guanidine hydrochloride. (B) 6M Guanidine hydrochloride. Lane 1) 
Page-Ruler Protein Ladder. Lane 2) Soluble protein fraction. Lane 3 & 4) Insoluble protein fraction from 
pellet rinse washes using 2M Urea. Lane 5) Resolubilized insoluble protein fraction using 6M Guanidine 
hydrochloride. 
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Following resolubilization of insoluble FliC-Stx2B, dialysis refolding using a refolding 
buffer devoid of guanidine hydrochloride was conducted to return the protein to a more intrinsic 
form (Fig. 3.23A). FliC-Stx2B (Fig. 3.23A, lane 5) shows an increase in band presence overall, 
however did not contain guanidine hydrochloride unlike in the resolubilized FliC-Stx2B sample. 
Both resolubilized and dialyzed FliC-Stx2B samples however showed similar banding patterns 
when compared to on-column purified samples, specifically polymerized protein bands located at 
~105-120kda (Fig. 3.23). Refolded FliC-Stx2B was then subsequently purified using nickel 
column affinity under the same parameters as on-column purification with the exception of on-
column incubation (Figs 3.17 & 3.19) in Fig. 3.24. 
 
  
Figure 3.23 Resolubilized, refolded, & on-column purified FliC-Stx2B 
(A) Dialyzed FliC-Stx2B. Lanes 1 & 10) Page-Ruler Protein Ladder. Lane 3) Resolubilized FliC-Stx2B 
using 2M Gnd-HCl. Lane 5) Dialyzed & refolded resolubilized FliC-Stx2B. (B) On-Column purified 
FliC-Stx2B. Lanes 1 & 10) Page-Ruler Protein Ladder. Lane 2) 1-hour on-column refolded FliC-Stx2B 
purified protein. Lane 4) 1-hour on-column refolded FliC-Stx2B purified protein. Lane 6) 6-hour on-
column refolded FliC-Stx2B purified protein. Samples were treated with 6M Gnd-HCl prior to nickel 
column purification.  
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Figure 3.24 Dialysis refolded FliC-Stx2B purified samples  
Resolubilized & refolded FliC-Stx2B samples purified using nickel column affinity. 
 
 
3.13 Dialyzed FliC-Stx2B Western Blot & Indirect ELISA analysis  
In order to determine both purity & biological activity for the FliC-Stx2B fusion protein, 
a Western blot and indirect ELISA was conducted on both resolubilized and dialyzed samples 
(Fig. 3.25 & 3.26). Western blot analysis seen in Fig. 3.25A & 3.25B (lanes 3, 5, 7, & 9) show 
positive biological activity against anti-Stx2B monoclonal antibodies. This is also seen across a 
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concentration gradient from 10ug-2.5ug in dialyzed FliC-Stx2B samples. Higher protein bands 
seen previously in Fig. 3.23A were also identified as containing the Stx2B epitope (Fig. 3.25).  
Indirect ELISA analysis (Fig. 3.26) shows positive biological activity for both 
resolubilized and dialysis refolded FliC-Stx2B samples across a concentration gradient of 250ug 
to 3.9ug. Biological profiles between both sample types were similar in activity. 
 
 
 
Figure 3.25 SDS-PAGE & Western Blot for resolubilized & purified dialyzed FliC-Stx2B 
(A) Lanes 1 & 11) Page-Ruler protein ladder. Lane 3) Resolubilized FliC-Stx2B. Lane 5) Dialyzed FliC-
Stx2B (10ug). Lane 7) Dialyzed FliC-Stx2B (5ug). Lane 9) Dialyzed FliC-Stx2B (2.5ug). (B) All lanes 
correspond to (A). Anti-Stx2B primary mAb was used at a ratio of 1: 1,000.  
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Figure 3.26 FliC-Stx2B resolubilized & dialysis refolded indirect ELISA 
Resolubilized & dialysis refolded FliC-Stx2B protein samples tested over a concentration range of 250ng-
3.9ng. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
3.14 Native-FliC  
Cells containing Native-FliC, inserted into the host plasmid pJ404, were expressed then 
separated into both soluble and insoluble fractions (Fig. 3.27). Expression of Native-FliC is seen 
in equal parts for both soluble and insoluble fractions, however does not appear in uninduced 
samples.  
 
Figure 3.27 Native-FliC soluble & insoluble induction samples  
 
 
3.15 Insoluble Native-FliC clarification & resolubilization  
Native FliC cell pellet sample was processed the same way described for FliC-Stx2B, and 
then clarified to remove excess proteins and inclusion bodies (Fig. 3.28). Following the detergent 
washes in lanes 3 & 4, the resolubilized Native-FliC insoluble protein lane shows an increased 
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reduction in non-desired protein. The corresponding Western blot confirms the activity of 
Native-FliC (Fig. 3.28) while showing no positive banding against purified FliC-Stx2B. 
 
Figure 3.28  SDS-PAGE & Western Blot (anti-FliC) for insoluble Native-FliC cell 
clarification 
SDS-PAGE: Lanes 1 & 15) Page-Ruler® protein ladder. Lane 2) Soluble protein fraction. Lane 3 & 4) 
Pellet detergent washes 1 & 2. Lane 5) Resolubilized Native-FliC insoluble protein. Lane 6) Purified 
FliC-Stx2B. Western Blot: All lanes correspond to SDS-PAGE. 
 
 
3.16 Native-FliC on-column refolding & purification  
Purification of resolubilized Native-FliC was conducted using AKTA® FPLC systems 
using the same parameters as the aforementioned FliC-Stx2B purification, however at a lower 
imidazole concentration gradient (5-100mM imidazole). It was observed (Fig. 2.29) that elution 
of nickel column bound Native-FliC began at 30mM imidazole and produced pure protein 
banding at ~60mM imidazole during the elution gradient, when using a 0.3mL/min flow rate.  
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Figure 3.29 SDS-PAGE for Native-FliC AKTA© FPLC Purification 
Lanes 1 & 15) Page-Ruler protein ladder. Lane 2) Resolubilized Native-FliC insoluble protein. Lane 6) 
5mM Imidazole wash. Lane 8) 30mM imidazole elution. Lane 10) 60mM imidazole elution. 
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4 CONCLUSIONS 
4.1 mRFP 
In silico design for mRFP was proven successful following PCR amplification (Fig. 3.1) 
producing large quantities of mRFP DNA from the host plasmid pSB1AC3. The high 
concentration of amplified DNA yield further allowed sufficient working material for subsequent 
down-stream applications such as; restriction digest, ligation, and transformation. This is 
attributed to the high primer specificity generated during In silico design, ensuring that melting 
temperatures were within the appropriate accuracy range based upon their G-C base pair content.  
Transformation of mRFP recirularized DNA samples were successful and yielded 
numerous cream-colored colonies, indicative of E. coli growth (Fig. 3.2). On selective control 
plates, no colonies were visible on plates containing solely electro-competent E. coli cells. No 
growth was also seen on plates inoculated with pJ404 plasmid DNA subjected to restriction 
enzyme double digest without the addition of DNA ligase. The presence of no growth with 
samples excluding DNA ligase illustrates that recircularization of the linearized plasmid did not 
occur during ligation, indicating efficient ligation of pJ404 vector plasmid and insert mRFP 
DNA.  
Colony PCR data supports this assessment (Fig. 3.3) as gene specific banding appeared at 
~700bp, similar to previously amplified mRFP DNA banding migration patterns. However, 
during protein expression, no fluorescence was observed. The transformant colonies also did not 
show any signs of fluorescence when subjugated to UV radiation at 240nm. Due to these results, 
it was presumed that fluorescence produced by mRFP was intrinsically weak and was unable to 
functionally emit observable levels. 
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4.2 Stx2B-1N in silico verification  
Previous work conducted on amplification of the toxoid gene of interest, Stx2B, from the  
host plasmid provided very small amounts of working insert DNA. Because of this, a redesign on 
previous in silico work was conducted in order to maximize starting DNA concentrations for 
subsequent experiments. Stx2B in silico gene analysis uncovered a competitive upstream SpeI 
restriction enzyme cut site located in host plasmid pJ204. Targeted insertion of Stx2B into 
synthetic FliC has the gene of interest located in the N’ terminus of synthetic FliC, between NcoI 
& SpeI restriction enzyme cut sites. Because of this, a competitive binding site for the Stx2B 
reverse primer was introduced due to SpeI being located on both the downstream end of the gene 
and the primer itself.  
In an attempt to optimize, PCR parameters were changed in order to enhance primer 
binding. These changes included; extending primer length, decreasing the concentration of 
template DNA over a gradient, and increasing the previous annealing temperature to 64°C. Each 
change was designed to increase specificity of the primers to template DNA during the annealing 
step, thus allowing primers to bind only to the specified region and not the competitive upstream 
restriction cut site. As shown in Fig. 3.4, decreasing the concentration of template DNA for PCR 
proved successful in producing a single amplified band, as a gradient like effect was seen when 
going down from 500ng to 100ng of template DNA. With these parameter changes established, 
high yields of concentrated amplicon DNA was produced for subsequent experiments for 
transformation. 
4.3 Stx2B-1N transformation & analysis 
With the higher yields of concentrated amplicon DNA for restriction enzyme digest and 
ligation, subsequent transformation and selective plating produced positive transformant 
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colonies. Colonies which grew on the selective LB plates with ampicillin exhibited similar 
growth characteristics, such as color & shape, as those seen with mRFP transformation.  
A quadrant colony PCR was conducted on several colonies per quadrant per plate for 
each molar ligation ratio (1:3 and 1:8) and yielded expected results (Fig. 3.6). Each quadrant, for 
each plate tested, showed Stx2B amplification from the transformant colonies. Thus, indicating 
that per quadrant tested, there was at least one colony that contained the Stx2B toxoid gene 
insert.   
Following these results, isolated colony PCR on several of the colonies that were used in 
quadrant colony PCR would be tested individually for PCR verification and to ensure no false 
positives (Fig. 3.7). The Stx2B toxoid gene insert again appeared on the gel following PCR, 
indicating that the Stx2B gene was inserted into host plasmid pJ404, which contains the histidine 
tagged synthetic FliC backbone. Restriction enzyme digest conducted on Stx2B-1N produced the 
gene of insert at the expected banding migration as seen in comparison to previous samples. 
DNA sequencing conducted at Georgia State University also confirmed Stx2B gene insertion at 
the correct location with no frame shifts or alterations to the in silico design. 
 
4.4 Stx2B-1N induction & purification analysis  
Induction on the Shiga-like toxoid containing E. coli cells (Fig. 3.13; Appendix A.3, 
A12-A14) showed that expression of the gene of interest was found primarily in insoluble 
fractions. Higher rates of gene expression were also seen at an optimal temperature of 37°C, and 
at an inducer concentration of 1.0mM Isopropyl β-D-1-thiogalactopyranoside (IPTG).  
Initial analysis conducted on clarified induced cell samples for purification (Fig. 3.8) 
showed that secretion of the recombinant protein, Stx2B-1N, maintains higher levels in the 
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soluble cell-associated fractions as opposed to insoluble fractions (Fig. 3.8 & 3.9). The presence 
of Stx2B-1N within the soluble intracellular fractions indicate that despite the addition of a 19 
mer signal peptide (‘MKKMFIAVLFALVSVNAMA’), a type 3 secretion system motif, the 
associated protein remains primarily within the soluble cell fraction and not within extracellular 
supernatant. This suggests that the induced rate for protein expression is either insufficient for 
translocation, or that Stx2B-1N remains adhered to the cellular transmembrane space during 
translocation. Moreover, during nickel column purification, eluted fractions for clarified Stx2B-
1N contained competitive non-specific protein which also demonstrated affinity for the column 
(Fig. 3.8).  
Because of this, troubleshooting techniques for enhanced fusion protein binding against 
nickel columns, and subsequent elution, were analyzed (Fig. 3.9). Enhancements to protein 
binding & elution was attempted through the usage of varying concentrations of imidazole in the 
binding buffer. Salt concentrations were increased from 2mM, to 5mM & 20mM of imidazole, 
respectfully (Fig. 3.9A & 3.9B). A decrease in excess non-specific protein during elution using 
20mM of imidazole (Fig. 3.9B) was observed in comparison to elution with the addition of only 
5mM of imidazole (Fig. 3.9A). The increase in imidazole enables previously competitive 
proteins, within a 20mM imidazole charged nickel column, to be removed during wash steps. 
However, this did not completely remove the remaining interfering proteins. 
 
4.5 Stx2B-1N fermentation analysis  
In order to produce large quantities of E. coli cell paste, containing the shiga-like toxoid 
subunit linked to synthetic FliC, a fed-batch fermentation was conducted and induced with IPTG 
for five hours. The cell paste, grown in ECAM synthetic media, was then processed into a 
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workable refined lysate and analyzed by SDS-PAGE & Western blot for protein expression 
levels. 
As it is seen in Fig. 3.10A & 3.10B, the protein of interest was expressed at a molecular 
weight of ~55kda, when using anti-FliC antibodies, throughout all the fractions during the 
clarification process. Another band, located at a molecular weight of ~38kda, was also seen and 
expressed at higher levels then the recombinant protein Stx2B-1N while appearing distinctly on 
the corresponding Western Blot.  
In order to isolate the expressed recombinant protein, several clarification steps were 
applied to the fermentation cell paste in order to remove non-desired proteins (Fig. 3.10). The 
SDS-PAGE ran on all sample fractions during homogenization, PEG 3350 precipitation, and 
Triton X-114 2-phase separation showed little removal of excess non-specific protein banding. 
Furthermore, the Western blot against anti-FliC antibodies showed an incremental decrease in 
the amount of Stx2B-1N recombinant protein throughout PEG precipitation and two-phase 
separation (Fig. 3.9B). Interestingly, the most prominent band on the Western blot was the 
~38kda protein band which became incrementally prominent during the separation phase.  
Analysis of the putative bands seen on the Western blot was conducted by Maldi-Tof 
MS/MS at Georgia State University’s protein core facilities department and confirmed the 
presence of Stx2B-1N. Whereas the ~38kda protein was identified as an outer membrane protein 
(OMP) commonly associated with E. coli cell fractions. 
 
4.6 FliC-Stx2B in silico design & transformation verification  
Previously, Stx2B-1N has shown expression in LB, TB, & E. coli Adaptation Mediums, 
respectfully. However, this level of expression appeared basal in comparison to other 
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recombinant protein expression levels pertaining to Stx2B. In order to enhance the level of 
expression a new clone series was designed and inserted into vector plasmid pJ404, containing 
synthetic FliC, into the C-terminal D0 domain in order to enhance hexa-histidine tag presentation 
during the purification process, and is aptly named FliC-Stx2B. 
More importantly as described above, FliC-Stx2B was designed & cloned with the 
exclusion of its native signal peptide motif to further enhance protein expression. It has been 
shown empirically by other researchers that the inclusion of the signal peptide can alter protein 
expression making it non-ideal for large yields following purification (Skinner & Jackson, 1998; 
Leung, et al., 2002)  
As described above, the toxoid subunit Stx2B was inserted into host plasmid pJ404 into 
the N’ terminal end of synthetic FliC with the concurrent omission of its’ signal peptide motif, 
and addition of flanking restriction enzyme cut sites & hexa-histidine tag.  Restriction enzyme 
digest, ligation, & transformation were conducted and produced transformant colonies which 
were verified to contain the Stx2B toxoid subunit by isolated colony PCR & restriction enzyme 
digest (Fig. 3.11 & 3.12). 
 
4.7 FliC-Stx2B induction & clarification analysis  
As it is seen Fig. 3.13, a small-scale flask induction was conducted using both Stx2B-1N 
and FliC-Stx2B expressing E. coli (BL21) cells in ECAM with induced IPTG concentrations of 
0.4 & 1.0mM. When analyzing the processed samples, the desired proteins appeared mainly in 
the insoluble fractions in both clones. In addition, both 0.4mM & 1.0mM IPTG induced culture 
samples showed qualitatively the same level of expression, whereas the uninduced fractions did 
not contain the protein of interest indicating tight promoter control.  
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Separate FliC-Stx2B expressing E. coli cultures were also induced (Fig. 3.14) using the 
same concentrations of IPTG; however, grown in LB, TB, & ECAM for preliminary induction 
analysis. Expression of FliC-Stx2B, which has a molecular weight of ~53kda, is found mainly in 
the insoluble fraction although it is also seen in the soluble fractions, however very slight.  
The level of expression seen in ECAM flask work in comparison to Stx2B-1N induced 
culture samples also appears to be qualitatively more significant. Suggesting that the removal of 
the signal peptide sequence could potentially have an effect in the recombinant protein’s 
translocation, post-expression (Selyunin & Mukhopadhyay, 2015). Another correlation presented 
is the decrease in prominence of non-desired protein bands when comparing uninduced & 
induced FliC-Stx2B samples. Specifically, this decrease is observed with an outer membrane 
protein (Omp), ~38kDa, commonly seen within induced insoluble samples.  
In order to isolate and purify insoluble FliC-Stx2B, processing methods needed to focus 
on resolubilization and removal of any inclusion bodies or improperly folded protein. This was 
achieved by using a detergent wash method, using medium to saturating levels of detergents such 
as Urea and Guanidine Hydrochloride (Fig. 3.15 & 3.16). By washing the insoluble pellet, 
separated from the soluble protein fraction, it was shown that removal of non-desired proteins 
increased following each wash step performed. Interestingly, following the detergent washes, 
removal of most non-desired proteins was achieved when resolubilizing the insoluble pellet 
sample in guanidine hydrochloride rich binding buffer, leaving an almost pure sample of FliC-
Stx2B prior to protein purification, (Appendix A.3, A16-A20).  
However, it is important to note that with each wash step performed removal of FliC-
Stx2B also occurred. The banding pattern for resolubilized pellet samples on the SDS-PAGEs 
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also migrate slightly higher as a result of the extra salt concentration provided by Guanidine 
Hydrochloride. 
In order to determine whether or not the processed samples contained biological epitope 
activity, a Western blot was conducted alongside the corresponding SDS-PAGE (Fig. 3.16). 
Results showed that expressed FliC-Stx2B contains biological activity for anti-Stx2B antibodies 
in all fractions, with the exception of the separated soluble fraction. This further supports the 
theory that the exclusion of Stx2B’s native signal peptide may lead to sequestration of the 
protein in insoluble cytoplasmic compartments within the cell, as opposed to other translocation 
pathways. Polymer FliC-Stx2B protein complexes were also observed on the Western blot at 
~110-140kDA.  These bands however began to decrease after subsequent detergent washes 
during cell clarification, and with the inclusion of reducing agents during sample processing for 
SDS-PAGE. 
 
4.8 FliC-Stx2B on-column purification time studies & in vitro analysis  
Since the isolated protein following cell clarification was treated with medium to high 
concentrations of denaturing detergents, a refolding step to properly refold the denatured proteins 
while adhered to the nickel column was conducted using AKTA® FPLC systems. With the 
addition of the hexa-histidine tag to the synthetic FliC construct, refolding and purification could 
be done simultaneously, allowing for a more rapid throughput in regard to purification times. 
Analyzed elution samples show purified FliC-Stx2B elution at 60-80% of the step-wise elution 
gradient (Fig. 3.17 & 3.19; Appendix A.3, A21-A23). Additionally, each refolding time-point 
purification showed protein elution at the same 60-80% illustrating consistent elution 
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characteristics for FliC-Stx2B. Yields for solubilized pellet samples (prior-AKTA® FPLC) and 
de-salted purified FliC-Stx2B showed ~70% retention of the desired protein.  
Following elution, pure two-hour refolded FliC-Stx2B samples were subjected to in vitro 
analysis utilizing indirect-ELISA to quantitatively determine their biological activity against pre-
purification non-refolded FliC-Stx2B. This would in effect determine the refolding efficiency 
while the recombinant protein is bound to the nickel column. As it is shown in Fig. 3.18, purified 
FliC-Stx2B shows a higher rate of activity per concentration of sample tested. It also shows 
levels of saturation at roughly 0.00625ng & 150ng (low and high). This data suggests that 
refolding of the solubilized protein is necessary in order to activate higher levels of Stx2B 
epitope affinity. 
One & six-hour refolded FliC-Stx2B samples were also subjugated to in vitro analysis 
following elution (Fig. 3.19) to quantitatively determine their biological activity. Compared test 
samples included FliC-Stx2B refolding time-points and negative control RSV-N, which utilizes 
the same synthetic FliC platform but does not contain the Stx2B toxoid. Comparing the refolding 
efficiencies of refolded his-tagged FliC-Stx2B protein bound to the HisTrap nickel column 
overtime further characterizes FliC-Stx2B’s biological activity profile.  
As it is seen in Fig. 3.19 & 3.20, purified 1 hour refolded FliC-Stx2B shows a higher rate 
of activity per sample concentration tested than samples subjugated to 6 hours. It also shows 
levels of saturation at roughly 7.8ng & 125ng (low and high). This data suggests that refolding 
times necessary for biological activity retention can be relatively short, and as low as 1 hour. 
Furthermore, biological activity needed for adaptive immunity, seen between refolding time-
point samples, did not show any significant decrease indicating a faster throughput FliC-Stx2B 
production. 
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Moreover, preliminary activation of TLR5 receptors which are associated with APC 
maturation and pro-inflammatory cytokine response (Fig. 3.21) showed comparable TLR5 
activation against the known agonist control flagellin protein FljB. The fusion protein, FliC-
Stx2B, utilizes both an innate (synthetic FliC) and adaptive (Shiga toxoid 2, subunit B) immune 
system component for a potential humoral affect. By using a two-pronged approach, the innate 
response activating component of FliC-Stx2B may initiate innate cell maturation; allowing a 
humoral response through antigenic presentation on APCs and subsequent T cell maturation to 
occur, (Leigh, et al. 2014; Osterhaus, 2014; Sabag & Lorberboum-Galski, 2014; Song, et al. 
2014, Tarahomojoo, 2014). Activation and maturation of T cells specifically against the epitopic 
portions of FliC-Stx2B may then produce antibodies directly targeted against the attachment 
pentamer forming protein Stx2B, (Sandvig, 2000; Houdouin, et al., 2004; Fuller, et al., 2011; 
Scheutz, et al., 2012). 
 
4.9  FliC-Stx2B dialysis refolding, purification, & in vitro analysis  
Protein expression of the FliC-Stx2B fusion protein has been seen in previous works, 
enhanced by the removal of the signal peptide motif associated with the B subunit of Stx2. This 
expression, in comparison to previous FliC fusion protein Stx2B-1N, shows a higher rate of 
recombinant protein production when induced during cell culturing. FliC-Stx2B remains 
primarily an insoluble protein following separation of soluble and insoluble cell fractions (Fig. 
3.13 & 3.14). However, the presence of non-desired protein is still present, and further 
processing is necessary. A resolubilization procedure conducted on insoluble fractions (Fig. 3.15, 
3.16, & 3.22) using varying concentrations of detergents illustrated that isolation of FliC-Stx2B 
is possible and efficient. When comparing samples treated with either 2M or 6M Guanidine 
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hydrochloride in the binding buffer little variation is seen qualitatively on SDS-PAGE (Fig. 
3.22). In order to return FliC-Stx2B to an intrinsic form without the addition of on-column 
refolding, dialysis refolding methods were used (Fig. 3.23).  
Little difference was seen qualitatively on SDS-PAGE between resolubilized & dialyzed 
FliC-Stx2B with both samples exhibiting 90% FliC-Stx2B band presence (Fig. 3.23). It has been 
previously reported that FliC-Stx2B polymerizes and forms complexes which migrate higher on 
SDS-PAGE. In comparison, on-column purified FliC-Stx2B produced protein samples at ~98% 
purity when taking account of higher molecular weight polymerized proteins (Fig. 3.23B). In 
order to confirm the presence of polymerized FliC-Stx2B and other proteins containing the 
Stx2B epitope domain, a Western blot was conducted using anti-Stx2B monoclonal antibodies 
(Fig. 3.25A & 3.25B). As previously theorized, higher molecular weight polymerized protein 
bands seen (Fig. 3.25A) were confirmed for having biological activity against Stx2b mAbs (Fig. 
3.25B). This further supports the isolation & resolubilization methods used for FliC-Stx2B 
processing. Interestingly, bands appearing at ~60 & ~90kDa also appeared on the Western blot, 
while lower molecular weight bands did not.  
Biological activity for resolubilized & dialysis refolded FliC-Stx2B samples were further 
supported by showing positive anti-Stx2b activity along a varying concentration gradient on an 
indirect ELISA (Fig. 3.26). The data seen is consistent amongst both samples, indicating that 
FliC-Stx2b (when resolubilized with 2M Guanidine hydrochloride) contains a similar biological 
activity profile when compared to its refolded form. In previous studies, ELISA data gathered on 
resolubilized samples, using 6M Guanidine hydrochloride, illustrated a diminished biological 
activity profile in comparison to nickel column refolded & purified samples (Fig. 3.20). With 
these data, it can be theorized that using a detergent such as Guanidine hydrochloride, at a 
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concentration of 2M for protein resolubilization, is sufficient in isolating the FliC-Stx2B fusion 
protein while also maintaining its biological activity throughout the process. 
 
4.10 Native-FliC resolubilization & purification  
Native-FliC, inserted into vector plasmid pJ404, was also resolubilized using the same 
parameters as FliC-Stx2B above. Applying the same detergent wash method described above, 
6M guanidine hydrochloride, induced Native-FliC E. coli cells were disrupted, clarified, and 
analyzed on SDS-PAGE & Western blot (Fig. 3.27). Unlike with FliC-Stx2B, Native-FliC 
expression is seen in both the soluble and insoluble fractions, making the starting material 
needed for cell clarification significantly less in flask work. Despite this however, removal of 
non-desired proteins throughout detergent washes and final resolubilization was seen (Fig. 3.28). 
Prior to purification, a Western blot against Native-FliC showed biological activity in both 
soluble and insoluble fractions, confirming the presence of the protein (Fig. 3.29).   
The resolubilized pellet sample produced during the detergent wash method was used for 
purification and passed through a nickel column using the same conditions as FliC-Stx2B 
purification. Previous Native-FliC purifications showed protein being washed off the nickel 
column when imidazole concentrations were at 20mM. Because of this, imidazole concentrations 
for Native-FliC samples were reduced to 5mM, and elution concentrations were reduced to a 
gradient of 5-100mM imidazole. Using these characteristics, resolubilized Native-FliC was 
eluted at a concentration of ~30-60mM imidazole during the elution gradient (Fig. 3.29). 
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4.11 Summary 
In summary, this work outlines the development of process methodology for the design, 
production, & characterization of a recombinant based fusion protein containing immunity 
activating FliC & a shiga-like toxoid subunit B protein.  The methodology presented herein may 
also directly be applied to other similar fusion based protein constructs located in cellular 
insoluble inclusion body fractions. The developed process overview is as follows; in silico 
design, induction studies, clarification & isolation, on-column & dialysis refolding purifications, 
qualitative analysis, & in vitro analysis.  
The removal of Stx2B’s intrinsic signal peptide led to a significant increase in starting 
material when induced, indicating fusion protein retention in the cytoplasm. A modified 
detergent wash method, utilizing guanidine hydrochloride, removed ~90-95% non-desired 
proteins while retaining FliC-Stx2B biological activity following refolding by dialysis or on-
column purification. Interestingly, samples resolubilized with 6M guanidine hydrochloride 
illustrated a lower activity profile against anti-Stx2B antibodies then samples processed with 2M 
guanidine hydrochloride. Purified protein yields ranged from 40-78%, and produced significant 
amounts of FliC-Stx2B that was further characterized to be biologically active against anti-Stx2B 
antibodies & TLR5 receptors. 
Future approaches to optimize this work should focus on further characterizing 
purification parameters such as nickel based, hydrophobic interaction, or size exclusion columns.  
Linear elution gradients conducted during purification will help to characterize elution time 
points/parameters, and further increase purified protein yields. Alternative methods for isolation 
and purification will also aid in streamlining workflow and preventing bottlenecking during 
production. 
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APPENDICES  
Appendix A 
Appendix A.1 Construct design 
 
Restriction Enzyme Cut Site Legend 
NcoI EcoRI XbaI SpeI BamHI HindIII XhoI NotI AatII AvrII Buffer bases 
 
Sequence after F1 and R1 primers: 
GGATCCATGAAGAAGATGTTTATGGCGGTTTTATTTGCATTAGCTTCTGTTAATGCAATGGCGGCGG
ATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGACACATTTACAGTGAAGGTTG
ACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCAACCGTTACTGCAAAGTGCTCAGTTGACAG
GAATGACTGTCACAATCAAATCCAGTACCTGTGAATCAGGCTCCGGATTTGCTGAAGTGCAGTTTAA
TAATGACACTAGT 
 
F1: 5’ – GGATCCATGAAGAAGATGTTTATGGCGGTT – 3’  
R1:  5’ –ACTAGTGTCATTATTAAACTGCACTTCAGC – 3’ 
 
 
Sequence after F2 and R2C (C’ Terminus) primers: 
CCATGGAAGGATCCATGAAGAAGATGTTTATGGCGGTTTTATTTGCATTAGCTTCTGTTAATGCAAT
GGCGGCGGATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGACACATTTACAGT
GAAGGTTGACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCAACCGTTACTGCAAAGTGCTCA
GTTGACAGGAATGACTGTCACAATCAAATCCAGTACCTGTGAATCAGGCTCCGGATTTGCTGAAGT
GCAGTTTAATAATGACACTAGTTAGGCGGCCGC 
 
F2: 5’ – CCATGGAAGGATCCATGAAGAAGATG – 3’         
R2C: 5’ – GCGGCCGCCTAACTAGTGTCATTATT – 3’ 
 
 
Sequence After F3 and R3C (C’ Terminus) primers: 
TCTTGCTTAACTCCATGGAAGGATCCATGAAGAAGATGTTTATGGCGGTTTTATTTGCATTAGCTTCT
GTTAATGCAATGGCGGCGGATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGAC
ACATTTACAGTGAAGGTTGACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCAACCGTTACTG
CAAAGTGCTCAGTTGACAGGAATGACTGTCACAATCAAATCCAGTACCTGTGAATCAGGCTCCGGA
TTTGCTGAAGTGCAGTTTAATAATGACACTAGTTAGGCGGCCGCAATGATATTTAT 
 
F3: 5’ – TCTTGCTTAACTCCATGGAAGGATCCATG – 3’          
R3C: 5’ – ATAAATATCATTGCGGCCGCCTAACTAGT – 3’                
 
A 1 Stx2B step wise PCR primer in silico design.  
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CCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAA
CAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAA
GGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGCCCAC
CACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTG
CCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGC
GGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGA
GATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTAT
CCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTA
TCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGG
GGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTT
TGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAG
CTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGGC
GAGAGTAGGGAACTGCCAGGCATCAAACTAAGCAGAAGGCCCCTGACGGATGGCCTTTTTGCGTTT
CTACAAACTCTTTCTGTGTTGTAAAACGACGGCCAGTCTTAAGCTCGGGCCCCCTGGGCGGTTCTGA
TAACGAGTAATCGTTAATCCGCAAATAACGTAAAAACCCGCTTCGGCGGGTTTTTTTATGGGGGGA
GTTTAGGGAAAGAGCATTTGTCAGAATATTTAAGGGCGCCTGTCACTTTGCTTGATATATGAGAATT
ATTTAACCTTATAAATGAGAAAAAAGCAACGCACTTTAAATAAGATACGTTGCTTTTTCGATTGATG
AACACCTATAATTAAACTATTCATCTATTATTTATGATTTTTTGTATATACAATATTTCTAGTTTGTTA
AAGAGAATTAAGAAAATAAATCTCGAAAATAATAAAGGGAAAATCAGTTTTTGATATCAAAATTAT
ACATGTCAACGATAATACAAAATATAATACAAACTATAAGATGTTATCAGTATTTATTATCATTTAG
AATAAATTTTGTGTCGCCCTTAATTGTGAGCGGATAACAATTACGAGCTTCATGCACAGTGAAATCA
TGAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATATGTGGAATTGTGAGCGCTCACAATT
CCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTTAGGAGGTAAAACACCATGGGAATTCG
GTCTAGAACTAGTGCAGCCGGCCAGGCGATTGCGAATCGTTTTACGGCGAACATCAAGGGTCTGAC
CCAAGCCTCTCGTAATGCAAATGATGGTATTAGCATCGCACAAACCACCGAAGGCGCGCTGAACGA
GATCAACAATAACTTGCAACGTGTCCGTGAGCTGGCAGTTCAGAGCGCGAACAGCACGAATAGCCA
GTCCGATTTGGACAGCATCCAGGCGGAGATTACGCAACGTTTGAACGAAATCGACCGCGTCAGCGG
TCAAACGCAGTTTAATGGTGTGAAAGTTCTGGCCCAGGATAACACCCTGACGATTCAGGTTGGCGC
AAACGACGGTGAAACGATTGATATTGACCTGAAGCAGATCAACAGCCAAACCCTGGGTCTGGACAC
CCTGAACGTGCAACAAAAGTATAAGGTGTCGGACACGGCCGCTACCGTGACCGGCGACGTCGATAC
TACGATTGCTGGGCCCAATAGTACTTTTAAAGCTAGCGCTACTGGTCTTGGTGAGCTCGACCAGAAA
ATTGATCATATGTTAAAATTTGATGATCAATTGGGAAAATATTACGCCCCGCGGACCGTTACGGGGG
GACGATCGAAAGATGGCTATTATACCGGTTCCGTTGATAAGACGGCATGCGAGGTGACTCTTGCTGT
GCACGCGACTTCCCCGCTTACGCGTGGACTACCTGCGACAAGATCTGAGGATGTGAAAAATCCTAG
GGTTGCCAACGCTGACCTGACCGAGGCGAAAGCGGCGCTGACCGCAGCGGGCGTTACTGGTACCGC
AAGCGTTGTGAAAATGAGCTACACCGACAATAATGGTAAAACTATCGATGGCGGTCTGGCGGTCAA
AGTCGGCGACGACTACTATTCCGCCACCCAGAACAAAGACGGCAGCATCAGCATTAACACTACGAA
ATACACCGCAGATGACGGCACGAGCAAAACGGCACTGAATAAGCTGGGCGGTGCGGATGGTAAGA
CCGAAGTTGTTAGCATTGGTGGTAAAACCTATGCCGCGTCCAAGGCAGAGGGTCACAATTTCAAGG
CGCAGCCGGATCTGGCGGAAGCTGCAGCGACCACGACCGAGAATCCGTTGCAGAAGATTGATGCGG
CGCTGGCACAGGTCGATACGCTGCGCTCTGACCTGGGTGCCGTACAAAACCGTTTCAATAGCGCGA
TCACCAATCTGGGCAACACCGTGAACAATCTGACCTCTGCTCGCAGCCGTATTGAGGGATCCGCGG
ATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGACACATTTACAGTGAAGGTTG
ACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCAACCGTTACTGCAAAGTGCTCAGTTGACAG
GAATGACTGTCACAATCAAATCCAGTACCTGTGAATCAGGCTCCGGATTTGCTGAAGTGCAGTTTAA
TAATGACCATCACCATCATCACCATCTCGAGTAGGCGGCCGCAAGCCCCAAGGGCGACACCCCATA
ATTAGCCCGGGCGAAAGGCCCAGTCTTTCGACTGAGCCTTTCGTTTTATTTGATGCCTGGCAGTTCC
CTACTCTCGCATGGGGAGTCCCCACACTACCATCGGCGCTACGGCGTTTCACTTCTGAGTTCGGCAT
GGGGTCAGGTGGGACCACCGCGCTACTGCCGCCAGGCAAACAAGGGGTGTTATGAGCCATATTCAG
GTATAAATGGGCTCGCGATAATGTTCAGAATTGGTTAATTGGTTGTAACACTGACCCCTATTTGTTT
ATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAA
TATTGAAAAAGGAAGAATATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATT
TTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGT
GCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAA
GAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACG
CCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGT
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CACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAG
TGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCA
AACGACGAGCGTGACACCACGATGCCTGTAGCGATGGCAACAACGTTGCGCAAACTATTAACTGGC
GAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGA
CCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCCGGAGCCGGTGAGCGTG
GTTCTCGCGGTATCATCGCAGCGCTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACAC
GACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGAT
TAAGCATTGGTAAGCGGCGCGCCATCGAATGGCGCAAAACCTTTCGCGGTATGGCATGATAGCGCC
CGGAAGAGAGTCAATTCAGGGTGGTGAATATGAAACCAGTAACGTTATACGATGTCGCAGAGTATG
CCGGTGTCTCTTATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCG
GGAAAAAGTGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGG
CGGGCAAACAGTCGTTGCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAAT
TGTCGCGGCGATTAAATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACG
AAGCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGAT
CATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCG
TTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTCCCATGAGGACGGTACGCG
ACTGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAAG
TTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAAATTCAGCCG
ATAGCGGAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAAT
GAGGGCATCGTTCCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCC
ATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATCTCGGTAGTGGGATACGACGATACCGAAGAT
AGCTCATGTTATATCCCGCCGTTAACCACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCG
TGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGAAGGGCAATCAGCTGTTGCCAGTCTCACT
GGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTC
ATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGACTCATGACCAAAATCCC
TTAACGTGAGTTACGCGCGCGTCGTTCCACTGAGCGTCAGAC 
A 2 FliC-Stx2B in pJ404 plasmid nucleotide sequence (5492 bp) 
 
 
 
 
 
A 3 Stx2B-1N bioinformatic predicted protein structure (Yang, 2015) 
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A 4 FliC-Stx2B in pJ404 plasmid map (Benchling®)  
 
 
 
A 5 FliC-Stx2B bioinformatic predicted protein structure, (Yang 2015) 
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Appendix A.2 Reaction volumes 
 
A 6 mRFP PCR volumes 
mRFP Template DNA 13.75µL 
mRFP Forward primer 2µL 
mRFP Reverse primer 2 µL 
Master Mix Buffer 25µL 
Nuclease free water 9.25µL 
Total Volume 50µL 
 
 
 
 
A 7 mRFP and pJ404 digest volumes 
  mRFP                                    pJ404  
Nco1 1µL Nco1 1µL 
EcoR1 2µL EcoR1 2µL 
Neb 3.1 
buffer 
5µL Neb 3.1 
buffer 
5µL 
DNA 2.5 µL DNA 10 µL 
Nuclease 
free water 
39.5 µL Nuclease 
free water 
35 µL 
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A 8 mRFP/pJ404 ligation volumes. 
Linearized pj404 vector DNA 100ng (1µL) 
Insert DNA 5 µL 
5x Rapid Ligation Buffer 4 µL 
T4 DNA ligase 1 µL 
Nuclease free water 9 µL 
Total volume 20 µL 
 
A 9 Step wise PCR parameters for Stx2b plasmid (pJ204). 
Template DNA 1µg 
Forward primer 2µL 
Reverse primer 2 µL 
Master Mix Buffer 25µL 
Nuclease free water — 
Total Volume 50µL 
 
 
 
A 10 PCR parameters for Stx2B-1N primers at varying DNA concentrations.  
 
1) 100ng DNA        2) 300ng DNA            3) 500ng DNA 
STx2Bfwd 1µL STx2Bfwd 1µL STx2Bfwd 1µL 
STx2Brev 1µL STx2Brev 1µL STx2Brev 1µL 
Master Mix 25µL Master Mix 25µL Master Mix 25µL 
Template DNA 
(STx2B/pJ204) 
100ng DNA 
1.2µL Template DNA 
(STx2B/pJ204) 
300ng DNA 
3.5µL Template DNA 
(STx2B/pJ204) 
500ng DNA 
5.7µL 
ddiH2O 21.8µL ddiH2O 19.5µL ddiH2O 17.3µL 
Total 50µL Total 50µL Total 50µL 
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A 11 Stx2B-1N ligation volumes. 
vector DNA 50ng 
Insert DNA 1.75 µL 
5x Rapid Ligation Buffer 4 µL 
T4 DNA ligase 1 µL 
Nuclease free water 4.63 µL 
Total volume 20 µL 
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Appendix A.3 Protein work 
 
A 12 STx2B-1N induction using 0.1mM IPTG.  
 
 
A 13 STx2B-1N induction using 1.0mM IPTG.  
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A 14 STx2B-1N induction using 5.0mM IPTG. 
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A 15 FliC-Stx2B expression & resolubilization.   
 
 
A 16 FliC-Stx2B resolubilized using 50rpm & 100rpm agitation.  
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A 17 FliC-Stx2B resolubilized using 250rpm & ~3000rpm agitation. 
 
 
A 18 FliC-Stx2B resolubilized using pulse vortex agitation & single isolation wash. 
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A 19 FliC-Stx2B resolubilized using 1M or 3M urea detergent washes. 
 
 
 
A 20 FliC-Stx2B resolubilized using detergent wash concentrations. 
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A 21 One-hour refolded FliC-Stx2B purification. 
 
 
A 22 Three-hour refolded FliC-Stx2B purification. 
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A 23 Six-hour refolded FliC-Stx2B purification. 
 
A 24 FliC-Stx2B refolding purification AKTA® FPLC chromatogram.  
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A 25 FliC-Stx2B fed-batch fermentation in ECAM.  
 
 
 
 
A 26 LDS test for guanidine hydrochloride retention.  
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Appendix A.4 Media & Buffer list 
Media: 
 
SOB (1L) 
20g Tryptone 
5g Yeast extract 
0.5g NaCl 
2.4g Magnesium sulfate anhydrous 
286mg Potassium chloride 
diH2O 
pH 6.8-7.0 
 
Luria Broth (1L) 
10g Tryptone 
10g NaCl 
5g Yeast extract 
diH2O 
pH 7.0 
 
Terrific Broth (1L) 
12g Tryptone 
24g Yeast extract 
4mL Glycerol 
2.31 g Potassium phosphate monobasic 
12.54g Potassium phosphate dibasic 
diH2O 
pH 7.0 
 
E. coli adaptation media (1L) 
7.8g KH2PO4  
1.0g Citric acid  
2.33g (NH4)2SO4  
1mL Trace metal solution  
1mL Thiamine HCl solution  
40mL Glucose stock solution  
13mL MgSO4 solution  
0.5mlL CaC12 solution  
50mg Carbenicillin  
34mg Chloramphenicol  
diH2O 
pH 7.2 
 
 
 
 
98 
Buffers: 
 
Super Q equilibration buffer (1L) 
20mM Tris 
diH2O 
pH 7.2 
 
B80 Lysis buffer (1L) 
50mM Tris 
125mM NaCl 
10mM EDTA 
4% Sucrose 
diH2O 
pH 8.0 
 
Pellet resuspension buffer (B57, 1L) 
100mM Tris 
8M Urea 
diH2O 
pH 8.0 
 
Resuspension buffer (1L) 
20mM Tris 
diH2O 
pH 8.0 
 
Isolation buffer (1L) 
2M Urea  
20mM Tris  
0.5M NaCl  
2% Triton X-100  
diH2O 
pH to 8.0 
 
Binding buffer (1L) 
6M Guanidine Hydrochloride 
20mM Tris 
0.5M NaCl 
20mM Imidazole 
1mM DTT 
diH2O 
pH 8.0 
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Solubilization buffer (1L) 
6M Urea 
20mM Tris 
0.5M NaCl 
20mM Imidazole 
1mM DTT 
diH2O 
pH 8.0 
 
Refolding buffer (1L) 
20mM Tris 
0.5M NaCl 
20mM Imidazole 
1mM DTT 
diH2O 
pH 8.0 
 
Elution buffer (1L) 
20mM Tris 
0.5M NaCl 
0.5M Imidazole 
1mM DTT 
diH2O 
pH 8.0 
 
PBST (1L) 
0.05% Tween 20 in Phosphate-buffered saline 
diH2O 
pH 7.4 
 
50X TAE (1L) 
242g Tris base 
57.1mL Glacial acetic acid 
100mL EDTA (500mM) 
diH2O 
pH 8.0 
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ELISA substrate solutions: 
 
ELISA Coating buffer (1L) 
1.5g Sodium Carbonate anhydrous 
2.93g Sodium Bicarbonate 
diH2O 
pH 9.6 
 
 
ELISA Wash buffer (1L) 
8.0g Sodium Chloride 
0.2g Potassium Chloride 
1.15g Sodium Phosphate dibasic anhydrous 
0.2g Potassium Phosphate monobasic 
0.05% Tween 20 
5% Nonfat dry milk 
diH2O 
pH 7.4 
 
ELISA Blocking buffer (1L) 
5% Non-fat dry milk in PBST 
diH2O 
pH 7.4 
 
TBST solution buffer (1L) 
20mM Tris-HCl  
0.15mM NaCl 
1% Triton X-100 
diH2O 
pH 7.4 
 
TBST-Milk solution buffer (1L) 
20mM Tris-HCl  
0.15mM NaCl 
1% Triton X-100 
5% nonfat dry milk 
diH2O 
pH 7.4 
 
